Name of journal: *World Journal of Pharmacology*

ESPS Manuscript NO: 12938

Columns: REVIEW

**Carbapenemases: A worldwide threat to antimicrobial therapy**

Sahuquillo-Arce JM *et al.* Carbapenemases threat

José Miguel Sahuquillo-Arce, Alicia Hernández-Cabezas, Fernanda Yarad-Auad, Elisa Ibáñez-Martínez, Patricia Falomir-Salcedo, Alba Ruiz-Gaitán

**José Miguel Sahuquillo-Arce,** Grupo de investigación de infecciones respiratorias, Instituto de Investigación Sanitaria - Fundación para la Investigación Hospital La Fe, Torre A, 46026 Valencia, Spain

**Alicia Hernández-Cabezas, Fernanda Yarad-Auad, Elisa Ibáñez-Martínez, Patricia Falomir-Salcedo, Alba Ruiz-Gaitán,** Servicio de Microbiología, Hospital Universitari i Politécnic La Fe, 46009 Valencia, Spain

**Author contributions:** All authors contributed equally to this manuscript.

**Conflict-of-interest:** The authors declare they have no conflicts of interest.

**Open-Access:** This article is an open-access article which selected by an in-house editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: José Miguel Sahuquillo-Arce, MD,** Grupo de investigación de infecciones respiratorias, Instituto de Investigación Sanitaria - Fundación para la Investigación Hospital La Fe.,Bulevar Sur, s/n, Hospital U. y P. La Fe, Torre A, Planta 6ª,46026 Valencia, Spain.wadjur@hotmail.com

**Telephone:** +34-96-3862764

**Received:** July 29, 2014

**Peer-review started:** July 29, 2014

**First decision:** October 16, 2014

**Revised:** November 14, 2014

**Accepted:** November 27, 2014

**Article in press:**

**Published online:**

**Abstract**

Carbapenems are potent β-lactams with activity against extended-spectrum cephalosporinases and β-lactamases. These antibiotics, derived from thienamycn, a carbapenem produced by the environmental bacterium *Streptomyces cattleya,* were initially used as last-resort treatments for severe Gram-negative bacterial infections presenting resistance to most β-lactams but have become an empirical option in countries with high prevalence of Extended Spectrum β-lactamase-producing bacterial infections. Imipenem, the first commercially available carbapenem, was approved for clinical use in 1985. Since then, a wide variety of carbapenem-resistant bacteria has appeared, primarily *Enterobacteriaceae* such as *Escherichia* *coli* or *Klebsiella* *pneumoniae*, *Pseudomonas* *aeruginosa* and *Acinetobacter* *baumannii*, presenting different resistance mechanisms. The most relevant mechanism is the production of carbapenem-hydrolyzing β-lactamases, also known as carbapenemases. These enzymes also inactivate all known β-lactams, and some of these enzymes can be acquired through horizontal gene transfer. Moreover, plasmids, transposons and integrons harboring these genes typically carry other resistance determinants, rendering the recipient bacteria resistant to almost all currently used antimicrobials, as is the case for *Klebsiella* *pneumoniae* carbapenemase - or New Delhi metallo-β-lactamases-type enzymes. The recent advent of these enzymes in the health landscape presents a serious challenge. First, the emergence of carbapenemases limits the currently available treatment options; second, these enzymes pose a risk to patients, as some studies have demonstrated high mortality associated with carbapenemase-producing bacterial infections; and third, these circumstances require an extra cost to sanitary systems, which are particularly cumbersome in developing countries. Therefore, emphasis should be placed on the early detection of these enzymes, the prevention of the spread of carbapenemase-producing bacteria and the development of new drugs resistant to carbapenemase hydrolysis.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Carbapenemases; Origin; Evolution; Epidemiology; Multi-Drug-resistant bacteria

**Core tip:** Carbapenemase-producing bacteria were a rare curiosity 15 years ago, as these bacteria were primarily detected in hospital settings. However, now carbapenemase-producing bacteria are observed in farms, companion or wild animals and even in distant glaciers, becoming an epidemic. The relevance this subject has acquired can be easily demonstrated through a search in any medical database; more than 1500 articles have been published depicting the exponential isolation of these bacteria since 1990, with an alarming acceleration in the last seven years.

Sahuquillo-Arce JM, Hernández-Cabezas A, Yarad-Auad F, Ibáñez-Martínez E, Falomir-Salcedo P, Ruiz-Gaitán A. Carbapenemases: A worldwide threat to antimicrobial therapy. *World J Pharmacol* 2014; In press

**INTRODUCTION**

Carbapenems are potent β-lactams with activity against extended-spectrum cephalosporinases and β-lactamases. These antibiotics, derived from thienamycn, a carbapenem produced by the environmental bacterium *Streptomyces cattleya,* were initially used as last-resort treatments for severe Gram-negative bacterial infections presenting resistance to most β-lactams but have become an empirical option in countries with high prevalence of Extended Spectrum β-lactamase (ESBL)-producing bacterial infections.

Imipenem, the first commercially available carbapenem, was approved for clinical use in 1985. Since then, a wide variety of carbapenem-resistant bacteria has appeared, primarily *Enterobacteriaceae* such as *Escherichia* *coli (E. coli)* or *Klebsiella* *pneumonia*, *Pseudomonas* *aeruginosa* and *Acinetobacter* *baumannii*, presenting different resistance mechanisms.

The most relevant mechanism is the production of carbapenem-hydrolyzing β-lactamases, also known as carbapenemases. These enzymes also inactivate all known β-lactams, and some of these enzymes can be acquired through horizontal gene transfer via conjugation, transduction or transformation through outer membrane vesicles. Moreover, plasmids, transposons and integrons harboring these genes typically carry other resistance determinants, rendering the recipient bacteria resistant to almost all currently used antimicrobials, as is the case for *Klebsiella* *pneumoniae* carbapenemase (KPC) - or New Delhi metallo-β-lactamase (NDM)-type enzymes.

The recent advent of these enzymes in the health landscape presents a serious challenge. First, the emergence of carbapenemases limits the currently available treatment options; second, these enzymes pose a risk to patients, as some studies have demonstrated high mortality associated with carbapenemase-producing bacterial infections; and third, these circumstances require an extra cost to sanitary systems, which are particularly cumbersome in developing countries. Therefore, emphasis should be placed on the early detection of these enzymes, the prevention of the spread of carbapenemase-producing bacteria and the development of new drugs resistant to carbapenemase hydrolysis.

Carbapenemase-producing bacteria were a rare curiosity 15 years ago, as these bacteria were primarily detected in hospital settings. However, now carbapenemase-producing bacteria are observed in farms, companion or wild animals and even in distant glaciers, becoming an epidemic. The relevance this subject has acquired can be easily demonstrated through a search in any medical database; more than 1500 articles have been published depicting the exponential isolation of these bacteria since 1990, with an alarming acceleration in the last seven years.

The objective of this paper is to summarize the current understanding of the epidemiological, biochemical and diagnostic characteristics of carbapenemases.

**CLASIFICATION**

Carbapenem-hydrolyzing β-lactamases are classified according to Bush, Jacoby and Medeiros[1], updated in 2010[2], proposing a functional classification dividing β-lactamases into 4 groups (1-4) according to the target substrate and inhibition profile of these enzymes and the phenotypic expression of the clinical isolates (Table 1).

This functional classification correlates with the Ambler molecular classification[3], which divides β-lactamases into 4 classes (A-D) according to the amino acid sequence and spatial structure of these molecules. Two large families have been determined based on the hydrolysis active site: serine-β-lactamases (classes A, C and D), possessing a serine residue at the active center, and metallo-β-lactamases (class B), requiring the presence of one or two divalent Zn2+ cations[4].

***Serine carbapenemases***

**Class A carbapenemases (functional group 2f):** Class A carbapenemases hydrolyze carbapenems, cephalosporins, penicillins and aztreonam and are typically inhibited by clavulanic acid and tazobactam. Characteristically, imipenem susceptibility widely varies from actual resistance to a slight susceptibility reduction that is typically undetected in routine microbiological tests.

Class A carbapenemases have been detected in *Enterobacter cloacae*, *Serratia marcescens*, *Klebsiella* spp.and *E. coli* in the bacterial chromosome or in mobile elements[5-8].

Among these class A enzymes, KPC, SME (*Serratia* *marcescens* enzyme), IMI (Imipenem hydrolyzing Β-lactamase) and NMC-A (non metallo-carbapenemase of class A) are the most similar in structure, with the largest deviations observed in areas distant from the active site.

SME and the NMC-A/IMI group are the most important chromosomally encoded enzymes, sharing 97% amino acid sequence identity.

Class A carbapenemases enzymes occur rarely and spread depends on the clonal expansion of the bacteria harboring these enzymes. Class A carbapenemases are susceptible to broad-spectrum cephalosporins, but resistant to carbapenems, penicillins, aztreonam and first generation cephalosporins. The production of these enzymes is induced through imipenem and cefoxitin via an AmpC type LysR-dependent regulation system involving the proteins SmeR, ImiR and NmcR[9,10].

SMEs have been detected in a small number of *S. marcescens* isolates, whereas IMI/NMC group enzymes have been detected in *Enterobacter* spp[10,11].

KPCs are clinically the most relevant among plasmid-encoded class A carbapenemases. Not only do these enzymes hydrolyze almost all known β-lactams[12], but KPCs are also inserted in mobile genetic elements bearing resistance genes for antimicrobials other than β-lactams. Remarkably, *K. pneumoniae* accumulates and transfers virulence factors, such as plasmids, to other genera[13-17].

To date, 20 different types of KPCs, differing by 1-3 amino acid substitutions and presenting different hydrolysis profiles ([www.lahey.org/studies](http://www.lahey.org/studies)), have been described. Interestingly, these enzymes share 61% homology with SFC-1 from *Serratia fonticola*, another class A carbapenem[18].

KPCs efficiently hydrolyze nitrocefin, cefalotin, cephaloridine, benzylpenicillin, ampicillin and pireracillin and also imipenem, meropenem, cefotaxime and aztreonam, but with 10-fold lower activity. Remarkably, KPCs present weak hydrolyzing activity on cefoxitine and ceftazidime[4].

GES (Guiana extended spectrum) enzymes were initially classified as ESBL, but subsequent studies have demonstrated that GESs hydrolyze imipenem, although less efficiently. These enzymes have been detected in *P. aeruginosa* and *K. pneumoniae*, and to date, 24 GSE types have been described (www.lahey.org/studies).

**Class D (functional group 2df):** Class D β-lactamases, also known as OXAs due to their ability to hydrolyze oxacillin, are classified according to their hydrolysis spectrum. Broad-spectrum OXA enzymes hydrolyze carbapenems and represent a heterogeneous group including more than 100 genetically different enzymes subdivided into 9 clusters based on amino acid sequence (Table 2)[4]. Carbapenems are weakly hydrolyzed through OXA carbapenemases, rendering high MICs below the resistance cut-off value. Nevertheless, OXA-producing bacteria are typically resistant to carbapenems, reflecting concurrent resistance mechanisms, such as permeability defects or the production of other β-lactamases[19,20]. OXA carbapenemases are variably inhibited by clavulanic acid, sulbactam and tazobactam.

The vast majority of OXA carbapenemases, except the OXA-48 cluster, have been detected in *Acinetobacter* spp. isolates, primarily *A. baumannii*, presenting high resistance to carbapenems[21,22].

However, the OXA-48 cluster is the most important among class D carbapenemases. The activity of these enzymes is 10-fold higher than that of other OXA enzymes, and the OXA-48 cluster has been identified in *K. pneumoniae*, from which it has spread to other *Enterobacteriaceae*[23-27].

OXA enzymes hydrolyze penicillins and first generation cephalosporins, but have a weak activity on oxyimino-cephalosporins. OXA-163, an OXA-48-like enzyme with a single amino acid substitution and a four-amino-acid deletion, exhibits lower affinity for carbapenems, but is active on extended-spectrum cephalosporins and partially inhibited by clavulanic acid, mimicking an ESBL phenotypic profile.

**Class C (functional group 1e):** CMY-10 is the only carbapenem-hydrolyzing enzyme within class C β-lactamases. This enzyme is an extended-spectrum cephalosporinase, reflecting a three-amino-acid deletion in the R2-loop, and has been detected in *E. cloacae* in South Korea[28].

**Class B or metallo-β-lactamases (functional group 3):** Class B or metallo-β-lactamases (MBL) vary greatly in amino acid sequence and molecular structure, but share some features: a divalent cation, primarily Zn2+, for substrate hydrolysis; the hydrolysis of carbapenems, penicillins and cephalosporins, but not monobactams, such as aztreonam, reflecting low affinity interactions; and inhibition through metal chelators, such as EDTA, which inhibit the activity of these enzymes through Zn2+ sequestration.

In *Enterobacteriaceae*, the expected phenotype includes resistance to amino-, carboxy-, and ureido-penicillins, penicillin-clavulanate combinations, and cefoxitin; decreased susceptibility to piperacillin-tazobactam and oxyimino cephalosporins and elevated MICs compared with the epidemiological cut-off values[19].

MBLs are subdivided into three subclasses, B1, B2 and B3, depending on the primary amino acid sequence and the structural characteristics of the active site, presenting low homology[29].

B1 and B3 subclasses use two Zn2+ ions in the active site and have a broad hydrolysis spectrum, whereas subclass B2 employs a single Zn2+ ion in the active site and only shows activity on carbapenems[30].

MBLs have been detected in the bacterial chromosome and mobile genetic elements. MBLs in the bacterial chromosome were the first type studied, as these enzymes have been detected in environmental organisms or opportunistic pathogens, such as *Bacillus* *cereus*, *Aeromonas hydrophila*, *Chryseobacterium* spp. or *Stenotrophomonas maltophilia*[31,32].

Acquired MBLs are easily transferred among different species, as these enzymes can be inserted into mobile genetic elements. These MBLs are primarily classified as B1 subclass enzymes, likely reflecting increased predisposition for insertion into gene cassettes, integrons, transposons or plasmids[33,34].

NDMs have been recently described as MBLs with high dissemination tendencies and have become the most relevant enzymes within this family[35]. NDM-1 has been identified in *Enterobacteriaceae*, and Gram-negative non-fermenters[36,37]. Some variants, such as NDM-4, -5 and -7, present higher efficiencies of carbapenem hydrolysis[38]. The systematical association of NMDs with other resistance determinants and spread rapidity to other bacterial strains poses a serious challenge to sanitary systems worldwide.

IMP (active on imipenem) was first detected in Japan during the 80’s[39]. Since then, 48 different subtypes have been described in *Enterobacteriaceae* and Gram-negative non-fermenting rods, particularly *Pseudomonas* and *Acinetobacter*, worldwide (www.lahey.org/studies). These enzymes exhibit a high specificity for hydrolyzing cephalosporins and carbapenems and characteristically, exhibit low activity on temocillin[40]. Enzymatic kinetic differences have been identified among different subtypes, but with low clinical relevance.

VIMs (Verona integron-encoded metallo-β-lactamase), first identified during the 90’s, are currently detected worldwide[41], and 41 VIM subtypes have been described ([www.lahey.org/studies](http://www.lahey.org/studies)). VIM-1 and VIM-2 are distributed worldwide and spread easily. Typically, these enzymes exhibit a high specificity for hydrolyzing carbapenems, and different from IMPs, these enzymes also hydrolyze temocillin. The hydrolysis profile varies among different VIM subtypes with no clinical relevance[30].

SPM-1s (São Paulo metallo-β-lactamases) were first identify in Brazil in 2001[42]. These enzymes have a broad hydrolyzing profile, including penicillins, cephalosporins and carbapenems[43]; but due to the associated mobile genetic elements, these enzymes exhibit a low tendency toward spreading.

GIM-1s (German imipenemases) have only been identified in Germany, originally associated with *P. aeruginosa*; however, these enzymes have recently been identified in *Enterobacteriaceae*[4,38,44].

Other acquired MBLs, including SIM, AIM, DIM and the recently described KHM-1 in a Japanese isolate from 1997, exhibit a low dissemination range and are clinically less relevant.

**CARBAPENEMASES: MECHANISMS OF ACTION**

β-lactamases catalyze the hydrolysis of the β-lactam ring, using water in nucleophilic ring opening, generating an innocuous β-amino acid[45].

Classes A, C and D possess a serine amino acid in the active site, while class B carbapenemases are metallo-enzymes possessing a zinc in the active site[4].

The catalytic mechanism of serine β-lactamases involves acylation, which is common to serine-β-lactamases and penicillin-binding proteins (PBP), and deacylation, which is absent in PBPs and is the essence of antibiotic resistance through serine-β-lactamases[46].

***Class A carbapenemases***

Class A β-lactamases possess four catalytic residues (Ser70, Lys73, Ser130 and Glu166) and use water as a nucleophile.

First, Lys73 is deprotonated through a concerted double proton transfer from Lys73Nζ to Ser130Oγ and from Ser130Oγ to C3-carboxylate in the substrate; Lys73Nζ-Ser130Oγ-C3-carboxylate in the acyl-enzyme intermediate forms a hydrogen bond network. Second, the acyl-enzyme tetrahedral intermediate is formed, with Glu166 acting as a general base catalyst. This step is the rate-determining process. Third, Lys73 is protonated through the concerted double proton transfer from C3-carboxylate to Ser130Oγ and from Ser130Oγ to Lys73Nζ. Finally, the degraded substrate is detached from the enzyme in concert with the transfer of a single proton from Lys73Nζ to Ser70Oγ to cleave the C7-Ser70Oγ bond[47].

***Plasmidic class A carbapenemases: KPCs, GESs***

The active site of KPC-2 contains the catalytic Ser70 residue and harbors the deacylation water molecule that is primed through an interaction with Glu166, Asn170 and Ser70. The oxyanion hole formed by the nitrogen backbones of S70 and Thr237 is partially occluded by the side chain of Ser70, which is somewhat unusual for class A β-lactamases. Cys69, adjacent to Ser70, is involved in a disulfide bond formation with Cys238. This disulfide bond formation is characteristic of class A carbapenemases.

A comparison of the KPC-2 structure with that of non-carbapenemases and previously determined NMC-A and SME-1 carbapenemase structures revealed several active-site alterations unique to carbapenemases. An outward shift of the catalytic Ser70 residue renders the active sites of carbapenemases more shallow, likely facilitating easier access for bulkier substrates. Further space for the α-substituents is likely provided through shifts in Asn132 and Asn170 and concerted movements in the postulated carboxyl-binding pocket to facilitate substrate binding at a slightly different angle to accommodate these α-substituents. Thus, the structure of KPC-2 provides key insights into the carbapenemase activity of emerging Class A β-lactamases[48].

The importance of Asn170, a ligand for the hydrolytic water, is further supported by the lack of this residue in GES-1, an enzyme exhibiting characteristic active-site disulfide bond formation and possessing a structure similar to other known carbapenemases, but lacking carbapenem-hydrolyzing activity. Although Asn170 is replaced with a Gly in GES-1, this residue is present in GES-2 and other class A carbapenemases[49-52].

***Cromosomic Class A carbapenemases: NMCs, SMEs, and IMIs***

Cromosomic class A carbapenemases exhibit sequence differences compared with traditional class A β -lactamases, such as TEM-1 and SHV-1, likely contributing to the unique substrate specificity of these enzymes.

The activity of SME-1 reflects a highly distributed set of interactions that subtly alter the structure of the active-site pocket, although no single position uniquely contributes to carbapenem hydrolysis[53]. Nonetheless, Ser-237 is significant to the carbapenemase activity of SME-1[54]. SME-3 differs from SME-1 by a single amino acid substitution of Tyr for His at position 105 at the entrance of the active site, a position that plays a subtle role in the binding affinities of some substrates[6,10,11,55].

***Class D carbapenemases***

OXA enzymes present markedly different amino acid sequences, however the most characteristic feature is the presence of an unusual N-carboxylated lysine post-translational modification, a general base for the activation of the serine nucleophile in the acylation reaction, and deacylating water[56-58]. In the first step of the acylation reaction, nucleophilic Ser attacks the carbonyl carbon of the β-lactam ring, leading to ring cleavage and the formation of a stable carbapenem-enzyme acylate. In the second step of the acylation reaction, a water molecule attacks the same carbon, the Ser-carbapenem bond breaks and the inactivated ligand is released from the active site[59].

In addition, some OXAs form dimers, and a dimer–monomer equilibrium has been implicated in the kinetic behavior of these enzymes[60].

The strictly conserved residues that participate in the acylation and deacylation enzymatic reactions of class D β-lactamases include the Ser67 nucleophile[59,61,62], the carboxylated Lys70, which activates Ser67 and is essential for the deacylation reaction[63], and Lys212, which plays a role in the protonation of the antibiotic substrate in concert with the acylation reaction.

The active site of OXA-24 has two main elements. Catalytic Ser-81, Thr-82, Phe-83 and Lys-84 form the first element[62]. As well as establishing contacts with water molecules in the cleft, the hydroxyl group of Ser-81 establishes a weaker hydrogen bond with the Nζ of Lys-84 (3.35 Å) than that observed in other oxacillinases. The relative weakness of this interaction is compensated by the slight movement of Lys-84 within the crevice, forming a hydrogen bond with the side chain nitrogen of the conserved Trp-167.

The conserved motif Ser-128/X/Val-Ile represents the second active site element of OXA-24. The lateral hydroxyl chain of Ser-128 is accommodated in the direction of active serine Ser-81, forming hydrogen bonds with the neighboring residues. Another characteristic feature within this second element is the presence of a non-polar residue (Val-130) unique to class D enzymes and contributing to the broad substrate specificity of OXA-24.

A hydrophobic barrier established through the specific arrangement of Tyr-112 and Met-223 side chains, which define a tunnel-like entrance to the active site, determines carbapenem substrate specificity. This hydrophobic environment over the active site is stabilized through other hydrophobic contacts involving Thr-111, Trp-115, and Trp-221. The tunnel diameter regulates the shape and chemical nature of the antibiotics accessing the active site[64].

Unexpectedly, the structure of OXA-48 was similar to that of OXA-10, an enzyme without carbapenemase activity, indicating that the hydrolysis of these compounds depends on subtle changes in the active site region. Moreover, the active site groove of OXA-48 is different in shape, dimensions, and charge distribution from that of OXA-24[65].

In OXA-58, the deacylating water molecule approaches the acyl-enzyme species, anchored at Ser-83, from the alpha-face. Additional studies comparing OXA-24, OXA-48 and OXA-58 carbapenemases with OXA-10 support the theory that OXA carbapenemases retain the catalytic machinery associated with class D β-lactamases, and residues located close to the β5-β6 loop might play a role in the mechanism of carbapenem hydrolysis[66,67].

***Class B carbapenemases***

MBLs require zinc ions for β-lactam ring hydrolysis. The active site has two potential zinc ion binding sites, often referred to as sites 1 and 2[68-70]. His, Asn, Gln, Asp and Cys residues typically form the zinc ligands in the two binding sites, and these residues are not fully conserved between different MBLs.

It has been suggested that metal ions act as Lewis acids based on coordination to the peptide carbonyl oxygen, providing a more electron-deficient carbonyl carbon to facilitate nucleophilic attack. Thus, metal ions stabilize the negative charge developed on the carbonyl oxygen of the tetrahedral intermediate anion. In many other metallo-proteases, metal ions lower the pKa of the coordinated water, thereby increasing the concentration of the metal-bound hydroxide ion. Although different in nature from simple solvated ions, coordinated hydroxide ions are better nucleophiles than water[71].

C-N bond fission is the most energetically difficult process in peptide hydrolysis. This fission reaction could be facilitated through the direct coordination of the departing amine nitrogen to the metal ion[72]. Alternatively, a metal-bound water could act as a general acid catalyst, protonating the amine-nitrogen-leaving group to facilitate C-N bond fission.

The catalytic mechanism suggested for BCII from *Bacteroides fragilis* was based on the crystal structure of this enzyme at a resolution of 2.5 Å, showing only one zinc-ion bound to the enzyme at the His site. Following substrate binding, the zinc-bound water molecule, deprotonated by the Asp120 residue, attacks the carbonyl, forming a negatively charged tetrahedral intermediate, which is stabilized through interactions with the metal ion. The Asp120 residue donates a proton to the nitrogen, and C–N bond cleavage occurs, followed by product dissociation from the enzyme active site[73,74].

In this mechanism, the bridging hydroxide ion is responsible for the nucleophilic attack, generating a negatively charged intermediate, stabilized through the oxyanion hole of the enzyme. The apical water molecule bound to zinc is optimally positioned to donate a proton to the leaving nitrogen, and the newly formed hydroxide ion moves to occupy the vacated Wat1 site, followed by product dissociation from the enzyme active site. This mechanism was initially proposed to involve zinc coordination to the β-lactam nitrogen, which is unlikely because of the relatively low electron density of zinc due to amide-resonance. However, the increased basicity of this ion, suggests that nitrogen binding to zinc likely occurs once the tetrahedral intermediate is formed[72].

An unusual mechanism has been proposed for subclass B2 CphA from *Aeromonas hydrophila* based on the crystal structures of the free enzyme and a reaction intermediate between the enzyme and the substrate biapenem[75]. Nucleophilic attack is performed through a water molecule, which is not coordinated to zinc, but activated through His118 catalysis, followed by C–N bond fission, which occurs prior to nitrogen protonation. This proposed mechanism uses zinc as a Lewis acid to facilitate C–N bond fission and stabilize the leaving group[72,73], whereas most mechanisms use the zinc ion as a Lewis acid to stabilize oxyanion formation from the β-lactam carbonyl oxygen. Rearrangement of the proposed intermediate amine anion, whose negatively charged nitrogen is stabilized through an interaction with the zinc ion, generates a bicyclic intermediate, which is observed in the crystal structure, although this rearrangement might not occur in the active site of the enzyme. A solvent molecule replaces the water molecule used in the nucleophilic attack, protonates the nitrogen and releases the final product[71].

**ORIGIN OF CARBAPENEMASES**

Bacteria appeared on Earth approximately 3.5 billion years ago. Subsequently, these evolved, differentiated and adapted to new environments, initiating competition among different species for the many resources needed for survival.

One of the survival strategies of early microorganisms involved the production and secretion of antimicrobial molecules that would eliminate any competitor but not affect the producer. To this end, bacteria synthesize both antimicrobials and antimicrobial neutralizers from the molecules already present in the metabolic networks of these organisms. The next step in this biochemical warfare involved the development of resistance mechanisms in non-antimicrobial-producing bacteria. It has been suggested that antimicrobials developed from signaling molecules, such as those used in *quorum* sensing, while β-lactamases are primarily derived from PBPs, enzymes for the production and maintenance of the bacterial wall[76,77].

Currently, many different biochemical products with antimicrobial or resistance properties are found ubiquitously, as this biochemical warfare has been ongoing for billions of years. Thus, it is only now that we are beginning to understand antimicrobial resistance. β-lactams and β-lactamases regularly occur in nature, therefore to understand the origin and evolution of the carbapenemase enzymes, it is necessary to introduce and explain the term “resistome”, *i.e*., the global set of molecules that confer antimicrobial resistance to microorganisms[78]. According to this theory, antimicrobials act as selectors and mutation accelerators of the resistance mechanisms present in nature; then, these resistance mechanisms are selected and transferred from one bacteria to another, as horizontal gene transfer is advantageous in dynamic environments[79-81]. Moreover, the level of antimicrobial pressure will determine the evolutionary rate[78].

***Origin of serine β-lactamases***

PBPs are a group of transpeptidases, transglycosylases and carboxypeptidases belonging to the active-site serine family of enzymes, except for one Zn2+-dependent PBP. These enzymes have been divided into low- and high-molecular-weight molecules responsible for building and maintaining the peptidoglycan structure of the bacterial cell wall. To this end, PBPs are fixed to the inner bacterial membrane with the active site facing the periplasmic space[77]. Interestingly, these enzymes cluster into six different groups closely related to different β-lactamases, suggesting that these enzymes developed independently from PBPs under different selection pressures in a two-step evolution to acquire acylation/deacylation properties[77,82-84]. Hall *et al*[85,86] showed that serine β-lactamases are ancient enzymes, over two billion old, which form three different clusters: classes A and B are sister taxa, while class C separated earlier from a common ancestor of classes A and B[85,86]. Recently, a new family of PBPs, PBP-A, has been described in *Cyanobacteria*, and these enzymes represent an intermediate step between class A β-lactamases and PBPs[84].

Phylogenetic analysis revealed that class A carbapenemases generate six related branches sharing 32%-70% amino acid sequence identity and group together with other β-lactamases and low-molecular-weight class C PBPs[77]. This observation suggests that these clusters evolved from different ancestors[18].

Class A carbapenemases existed before carbapenems were clinically used, as chromosomally encoded SME-1 and IMI-1 were detected in *S. marcescens* and *E. cloacae*, respectively, a few years before imipenem was launched[7,10]. Thus, carbapenem use acted as a selector. Indeed, Walther-Rassmussen et al. conducted a phylogenetic analysis, and the resulting phylogram showed that NMC-A, SME, KPC and SFC-1 cluster together and could share a common ancestor with carbapenemase activity[18].

In contrast, GES and SHV-38 have different origins, and only SHV-38 has a known ancestor[87]. Both enzymes cluster with other ESBLs, indicating that the carbapenemase activity of these enzymes evolved through various mutations in response to carbapenem use[18].

Class D β-carbapenemases might have also been derived from low-molecular-weight class C PBPs, and similar to class A, these enzymes predated carbapenem clinical use, as the first member of this family, ARI-1 (subsequently referred to as OXA-23), was identified in 1985 from an *A. baumannii* isolate[88]. Interestingly, BlaR and MecA transducers are included in branches belonging to these β-lactamases, potentially representing reverse evolution from β-lactamases[77,83]. Most OXA carbapenemases are primarily chromosomally encoded in *Acinetobacter* spp. and might represent a natural component of some subgroups[89]. Other OXA carbapenemases have been identified in bacteria, such as *P. aeruginosa* or *Shewanella* spp. Notably, the most clinically relevant enzyme in this family is the OXA-48 cluster, which exhibits the highest carbapenem hydrolysis rate, is plasmid encoded and has been detected in *Enterobacteriaceae*. Interestingly, OXA-48 might have originated from *Shewanella xiamensis*, an environmental bacterium isolated from seepage water that harbors an OXA-48-like chromosomal gene, namely OXA-181. However, the genetic structure of blaOXA-181 is different from that of blaOXA-48, indicating an unrelated origin. Thus, *Shewanella* spp. might represent a reservoir for OXA-type carbapenemases[90-93].

***Origin of MBL***

MBLs belong to a superfamily whose members exhibit a four-layered αβ/αβ structure and share five conserved motifs. Many enzymes of this superfamily are involved in hydrolysis and redox processes, mRNA maturation and DNA reparation, suggesting that MBLs could represent divergent evolution from an early ancestor[94].

Bayesian phylogenic studies indicate that subclasses B1 and B2 form one cluster that split approximately 2.2 billion years ago and developed β-lactamase activity approximately 1 billion years ago, whereas B3 is older, splitting earlier from a common ancestor and developing β-lactamase activity approximately 2.2 billion years ago[94,95]. Therefore, although the 3-dimensional structure of these enzymes is similar, with structural features consistent with the enzymatic activity profiles, the amino acid sequences of MBLs significantly diverge[94,95].

MBLs are chromosomally encoded in bacteria from different *phyla*, including δ-*Proteobacteria*, which are primarily soil inhabitants and bacterial predators, harboring as many as 30 gene copies, *Firmicutes*, *Bacteroidetes*, and α-, β- and γ-*Proteobacteria*[96,97].

Environmental bacteria exposed to antimicrobial pressure might be a plausible source of MBLs. For example, the sequence analysis of the blaNDM-1-positive IncA/C plasmid revealed that the plant pathogens *Xanthomonas* spp. or *Pseudoxanthomonas* spp. might be the origin of the NDM-1 β-lactamase[98], the pLD209 plasmid containing the *Pseudomonas* *putida* blaVIM-2 is a mosaic of both clinical and environmental bacteria[99], or the blaIMP gene, found in bacteria isolated from glaciers[100].

**GENETIC CONTEXT**

The expansion of chromosomally encoded carbapenemases, such as SME, IMI or NMC, depends on clonal replication; therefore, although common pathogens can easily spread among humans, the clinical impact of these microorganisms is typically limited to sporadic and local outbreaks that can be controlled.

However, mobile genetic elements carrying carbapenemases are a greater threat and challenge. These elements can be interchanged between different species and rapidly spread beyond clinical control. Indeed, horizontal gene transfer can occur in natural environments and remain unknown.

Among class A, KPCs are the most successful enzymes[101]. blaKPC has been identified in *Enterobacteriaceae*, *Pseudomonas* and *Acinetobacter* species and is typically inserted in TN4401, a TN-3 based transposon that evolves and mobilizes genes at a high frequency[102-105]. Interestingly, blaKPC success has been associated with a single *K*. *pneumoniae* sequence type, ST-258, which harbors the TN4401 transposon. Naas et al suggested that the transposition of these elements into various-sized plasmids is a recent event[95].

GES has also been identified in different species worldwide, but this enzyme is associated with single outbreaks[4], although a new type of mobile genetic element, namely the integron mobilization unit, has been described for blaGES-5[106]. IMI-2 has been identified in plasmids in *E*. *asburiae* and *E.* *cloacae*, but the clinical import of this enzyme is minimal[107,108].

Class D carbapenemases are transferred from plasmids to bacterial chromosomes and vice versa[109]. blaOXA-23 has been identified in certain *A*. *baumannii* clones and is generally located in a Tn2006 transposon, bracketed by the ISAba1 insertion sequence and associated with other antimicrobial resistance islands[110]. blaOXA-48 is associated with TN1999 in *K*. *pneumoniae* and Tn1999.2 in *E*. *coli*, where an ISR1 insertion sequence transfers this enzyme from an IncL/M plasmid to the bacterial chromosome. The high conjugative frequency of this plasmid among *Enterobacteriaceae* accounts for its overall success[109,111,112].

Until the emergence of blaNDM type MBLs, blaVIM and blaIPM were the most successful enzymes in this family. These enzymes are associated with IncA/C, IncF, IncHI1, IncL/M, IncN, and IncK incompatibility group plasmids and intercountry, interhospital, intrahospital, interspecies, and intraclonal spread[113]. These genes have primarily been identified on class I integrons as gene cassette arrays with other antimicrobial and antiseptic resistance genes[114,115]. In contrast, in a surprisingly short period of time, the blaNDM gene has become the most disseminated MBL among countries and species[35,116]. However, blaNDM is harbored in highly transferable plasmids containing resistance genes to almost all known antimicrobials[116,117]. Indeed, blaNDM-1 is considered a chimera constructed in *A*. *baumannii* through the initial capture of a precursor gene by ISCR27 and subsequent fusion to the aphA6/ISAba125 promoter, which was incorporated into the existing large multi-resistance regions of different *Enterobacteriaceae* plasmids. The gene blaNDM-1 has been associated with the remnants of the Tn125 transposon, which was identified in the chromosomes or plasmids of *Acinetobacter* spp. and is positioned adjacent to a complete or truncated bleMBL gene[118-121]. The high genetic mobilization of blaNDM-1 has been demonstrated through reports of a new chromosomally located class I Tn402-like structure in *P*. *aeruginosa*[122].

CMY-10, the only class C carbapenemase, has recently been associated with a new complex class 1 integron within a conjugative plasmid[123].

**EPIDEMIOLOGY**

blaSME has been identified in some subpopulations of *S*. *marcescens* located primarily in the UK and sporadically in North America. This gene has been associated with single cases or small outbreaks, but the spread is most likely hindered through fitness costs associated with the expression of SME protein. However, recently, blaSME has been detected on a genomic island, SmarGI1-1, which can be excised and circularized, likely contributing to the dissemination of this gene among *S*. *marcescens*[4,18,124,125].

blaIMI/NMC-A has been identified in *Enterobacter* spp. in sporadic cases in the United States, France, Finland, Croatia, Argentina and China[4,38,126].

bla*KPC* was first described in *K*. *pneumoniae* in cases in the east coast of the United States, but has now been identified worldwide in other *Enterobacteriaceae* and Gram-negative non-fermenters[12,18,127]. The spread of bla*KPC* has become an endemic problem in the east coast of the United States, Puerto Rico, Colombia, Greece, Italy, Israel and the east coast of China, and regional or local outbreaks have been reported worldwide[101,128,129]. The high adaptability and inter-genera spread of KPC has been demonstrated by the first KPC-3 outbreak in Canada, involving five different *Enterobacteriaceae* in eight patients[130].

blaGES genes have been detected worldwide in both *Enterobacteriaceae* and Gram-negative non-fermenters, but these genes pose a minor challenge compared with blaKPC. Nevertheless, blaGES has been identified in plasmids recovered from environmental samples easily replicated in *E*. *coli* and *P*. *aeruginosa*[4,131].

OXA-48-like carbapenemases, a source of frequent nosocomial outbreaks, were first detected in Turkey, but has recently spread primarily across North Africa[132,133]. In France, The Netherlands and Morocco, OXA-48-like carbapenemases have been associated with *K*. *pneumoniae* ST395, suggesting geographical dispersion through immigration. OXA-181 is a growing concern in the Indian subcontinent, and sporadic cases have been reported worldwide, although most cases have been associated with this geographical area[38]. OXA-163 has also been identified in Argentina and Egypt [38].

Chromosomally encoded MBLs are ubiquitous in environmental bacteria, but acquired MBLs have recently become a global concern. IMP type carbapenemases were first reported in Japan in the late 1980s in *P*. *aeruginosa*, subsequently these enzymes were identified in *S*. *marcescens* and are currently primarily detected in *Enterobacteriaceae* and *Pseudomonas* across eastern Asia[38,39,134-136].

Similarly, VIM-type enzymes have primarily been detected in *Enterobacteriaceae* and *Pseudomonas*. These enzymes were first detected in the 1990s in Italy and France and are now endemic in Greece, Italy, Spain, South Korea and Taiwan[38,41,137,138].

However, the most challenging MBLs are undoubtedly, the NDM-type carbapenemases. These enzymes were first detected in *K*. *pneumoniae* and *E*. *coli* in a Swedish patient returning from India, showing the propensity for interspecies spread[117,139]. The Indian subcontinent has been identified as both the origin and reservoir, where the prevalence of these enzymes is approximately 5%-18%[140,141], but the Balkans has also been recently identified a reservoir for NDM-type carbapenemases[142]. NDM producers have been reported worldwide, associated with intercontinental travel[38]. Disturbingly, NDM producers are involved in nosocomial infections and community-acquired infections.

**CARBAPENEMASE COSTS**

The emergence of carbapenemase-resistant bacteria is a global health threat and a medical challenge, implicating an extremely high cost for hospitals. This cost is associated with prolonged hospital stays, higher health care expenses, and increased mortality, particularly when a second antibiotic is needed for better coverage of the causative pathogen[143]. Significantly, the length of stay in hospital, the hours of mechanical ventilation and the time spent on an intensive care unit also contribute to increased costs[144].

The actual cost of controlling infection has been associated with several factors, and some of these factors, such as new antimicrobial development (estimated at U$ 1 billion per drug), the need for increased surveillance within each hospital to determine problematic pathogens, enforced isolation procedures to control spread, and education (primarily interns, residents, and medical students who have not yet developed specific treatment habits), are unsuspected.

Other costs involve the aging population and the delivery of quality health care at reasonable prices[143]. For optimal economic understanding, considering that high-cost drugs can also be cost-effective, the clinicians, pharmacists and economists at each hospital should work together to achieve cost-savings with effective antibiotic therapy, rather than making choices based on drug-acquisition costs[144].

With regard to the host, particularly in multipathological patients, there is a synergy between the severity of the underlying disease and infection with a resistant microorganism. The consequences are higher mortality rates, extended hospitalization and increased costs[145]. A common problem in endemic settings or during outbreaks is that therapeutic options become limited and are not always optimal[146]. Consequently, the appropriate selection of the initial antibiotic therapy before susceptibility tests are available is difficult. Thus, patients under these conditions have poorer clinical outcomes. Indeed, the death rates associated with KPC producers are higher than 50%, while rates associated with MBL producers range from 18%-67%[101].

Other challenges include clinical laboratory testing and the obtained results. Ideally, rapid and optimal susceptibility tests are in demand, but each pathogen varies, even within the same family, reflecting delayed resistant pathogen identification, treatment errors and higher costs[143].

The ability to efficiently treat carbapenemase-producing bacterial infections requires a multifactorial approach, including continuous investigation, the development of new antibiotics and the adequate use currently available treatments, considering that the first approach starts with an appropriate means of infection control[147].

**CARBAPENEMASE DETECTION**

A series of non-molecular-based tests have been proposed for the detection and identification of carbapenemases, but none of these analyses have 100% specificity or sensitivity. Therefore, the use of routine susceptibility tests to detect carbapenem resistance should be followed by genotypic and phenotypic confirmation.

Accordingly, CLSI and EUCAST breakpoints for carbapenems have been significantly lowered to improve the detection of carbapenem-resistant isolates[148,149].

Both organizations recommend reporting carbapenem MICs, regardless of carbapenemase production, and suggest that special tests for carbapenemase detection be performed only for epidemiology purposes and infection control issues. However, partial or total susceptibility to carbapenems has been observed in carbapenemase producers, and carbapenem elevated MICs have been associated with decreased outer membrane permeability or the overexpression of other β-lactamases or chromosomally encoded AmpC cephalosporinases[101,150].

The detection of carbapenemase producers in clinical specimens is based on a careful analysis of the susceptibility results obtained from automated systems, liquid media or disc diffusion tests according to standardized guidelines. The CLSI and EUCAST have defined cut-off values for carbapenemase detection in *Enterobacteriaceae* because carbapenem MICs for carbapenemase-producing bacteria might be below the clinical breakpoints. However, while the CLSI values lie within the intermediate category, the EUCAST values lies within the susceptible range. According to EUCAST epidemiological cut-off values, meropenem offers the best sensitivity and specificity balance (Table 3). Imipenem shows a narrow range between the wild-type bacteria and carbapenemase producers, and ertapenem, although it presents excellent sensitivity, has a variable positive predictive value, depending on the carbapenemase prevalence and presence of different resistance mechanisms[151,152].

Day *et al*[153] recently evaluated the effectiveness of disc diffusion using faropenem to predict carbapenemase activity in *Enterobacteriaceae.* These authors concluded that a zone diameter of 6 mm for a 10 µg faropenem disc predicted carbapenemase activity with a sensitivity (99%) and superior speciﬁcity (94%) equivalent to any recommended screening indicator of carbapenemase activity. Moreover, most carbapenemase-producing isolates grow up to the disc, and consequently these bacteria are easily detected. Interestingly, a double inhibition zone with colonies growing up to the disc was observed for isolates carrying OXA-48 carbapenemase.

***Automated systems***

Automated systems present poor specificity and cannot distinguish carbapenemase producers from isolates with porin loss and ESBL or AmpC overproduction[152]. These systems might not reliably detect all carbapenemase producers[154], particularly when a single carbapenem is tested[153]. Additionally, discrepancies arise with automated systems, such as Vitek2, which reported meropenem MICs for KPCs that were significantly lower than those obtained through broth microdilution[155]. OXA-48 producers are also poorly detected.

The modification of antibiotic testing panels for the inclusion of synergy tests between carbapenems and β-lactamase inhibitors, such as boronic acid for KPCs, cloxacillin for AmpCs and dipicolinic acid or EDTA for MBLs, would facilitate more stringent interpretive criteria and improve speciﬁcity[156].

***Modified Hodge test***

The cloverleaf or modified Hodge test (MHT) is based on the inactivation of a carbapenem using carbapenemase-producing organisms. Brieﬂy, an inoculum of the indicator organism *E. coli* ATCC 25922, adjusted to 0.5 McFarland turbidity standards, is used to inoculate the surface of a Mueller-Hinton agar plate. After incubation for 10 min at room temperature, a disc containing 10 µg of meropenem is placed onto the agar plate. Subsequently, 3-5 colonies of the test organisms are inoculated in a straight line from the edge of the disc to the periphery of the plate. The growth of the indicator strain toward the meropenem disc is interpreted as a positive result for carbapenem hydrolysis.

CLSI recommends this test for screening purposes, except for *P. aeruginosa*. An optimization of MHT (PAE-MHT) using *K. pneumoniae* ATCC 700603 as an indicator has demonstrated 100% sensitivity and 98% specificity for detecting carbapenemase activity without indeterminate results, including KPC and carbapenem-susceptible MBL-producing *P. aeruginosa*[157].

The MHT works well for the detection of KPC and OXA-48 producers, but is time consuming, cannot distinguish the type of carbapenemase involved and, most importantly, false positive results have been observed with isolates producing CTX-M-type ESBL or AmpC β-lactamases at high level. Moreover, false negative results may occur, primarily among NDM producers. Adding zinc to the culture medium significantly improves the sensitivity in detecting NDM producers by increasing the stability of the enzyme or modifying porin expression[158]. The replacement of Mueller-Hinton agar with MacConkey agar also increases the sensitivity for MBL or OXA producers. The enhanced detection reflects the presence of bile salts in the medium, which improve the release of periplasmic enzymes[159].

A modification of the MHT using discs containing carbapenem supplemented with boronic acid, which inhibits both class A carbapenemases and AmpC β-lactamases, can be used to reduce the number of false positives compared with the MHT results obtained using discs containing carbapenem alone or carbapenem supplemented with cloxacillin, which only inhibits AmpC enzymes. The proposed procedure results in high sensitivity and specificity for class A carbapenemase detection, regardless of the carbapenem tested. A low performance level is observed only among mucoid phenotype strains[160].

Overall, MHT, although remaining a convenient screening assay, cannot be used as the sole method for the detection of carbapenemase-positive isolates in the clinical laboratory.

***Biochemical tests***

Biochemical tests based on the detection of β-lactam ring hydrolysis have been developed for the early identification of carbapenemases in *Enterobacteriaceae* and *P. aeruginosa*.

The Carba NP test is a colorimetric test based on the detection of acidification resulting from imipenem hydrolysis coupled with inhibitors that reliably identify carbapenemase producers and discriminate between the three main types of carbapenemases (Ambler classes A, B and D). Ambler classes A and B are inhibited through tazobactam and EDTA, respectively, while class D production is deduced from the lack of inhibition.

This test is highly sensitive and specific, easy to perform and interpret, cost-effective, adaptable to any laboratory, and the results are obtained within 2 h. Additionally, the Carba NP test is cheaper and faster than molecular techniques and can be used to select isolates for subsequent analyses using PCR methods[161,162].False negative results have been observed using this test, particularly for OXA-48 and GES[163].

The Carba NP test has been evaluated to directly detect carbapenemase-producing *Enterobacteriaceae* from positive blood cultures, yielding high sensitivity and specificity, which might be useful for the rapid detection of carbapenemase producers in endemic countries and outbreak situations and for the early implementation of appropriate antimicrobial therapies[164,165].

The Rapid CARB Screen Kit (Rosco Diagnostica A/S, Taastrup, Denmark) is another method based on the identification of β-lactam ring hydrolysis in the presence of an indicator. This kit is technically easier to use, but the results are more difficult to interpret, and this assay does not discriminate carbapenemase types. Furthermore, the number of false positives and uninterpretable results present another major disadvantage of this assay. Thus, this kit can be used for the direct detection of carbapenemases in positive urine and blood samples.

Both tests should be used with caution in areas with high OXA-48 prevalence and should be evaluated in epidemiological settings where carbapenemases with lower hydrolytic activity might be detected, *i.e.*, IMP, GES or OXA-198[166].

The Blue-Carba test is a variation of the Carba NP test, validated for the direct detection of carbapenemase-producing strains from bacterial cultures. This test uses tienam instead of the more expensive imipenem monohydrate. The sensitivity and specificity of the Blue-Carba test are similar to those of the Carba NP test, but the former has an additional advantage of detecting *Acinetobacter* OXA-type carbapenemases[167].

***Detection of MBLs based on chelating agents***

The phenotypic detection of MBL producers in the clinical laboratory is based on the specific inhibition of MBLs using zinc-depriving compounds, such as EDTA, dipicolinic acid, and 1,10-phenanthroline or thiol compounds, such as 2-mercaptopropionic and mercaptoacetic acid.

The double-disc synergy test (DDST) employs a disc containing hydrolyzable β-lactam (typically a carbapenem, although ceftazidime has also been widely used) placed near a disc containing an MBL inhibitor. The formation of a synergistic inhibitory zone indicates MBL production[168].

Alternatively, in the combined disc test (CDT), the inhibition zone of a disc containing β-lactam combined with an inhibitor is compared with that of a disc containing β-lactam alone. An increase in the inhibition zone diameter above a predefined cut-off value indicates MBL activity[169].

Based on similar principles, gradient diffusion methods (*e.g*., IP/IPI Etest, bioMérieux, France) use strips containing imipenem and imipenem plus EDTA. A MIC reduction greater than or equal to eight-fold in the presence of EDTA indicates MBL activity[170,171]. New E-test strips containing other inhibitors or carbapenem molecules would facilitate MBL detection, but these strips are not yet commercially available.

Another strategy to facilitate easy interpretation, regardless of the carbapenem MIC, is the use of an inhibitor-impregnated agar.EDTA-impregnated agar is prepared by spreading 2 mL of a 5 mnol/L EDTA solution on the surface of a Mueller Hinton agar plate (MH). Differences in the inhibition zone of the carbapenem discs are compared between inhibitor-impregnated and a regular MH agar, searching for differences ≥ 10 mm. This technique facilitates the easy detection of simultaneously associated mechanisms of β-lactam resistance and carbapenemase production in clinical isolates[172].

When using methods based on β-lactam–chelator combinations, it is important to consider the potentially detrimental effects of chelating agents on bacterial growth, which might yield false positive results.

***Detection of class A carbapenemases based on boronates***

The phenotypic detection of class A carbapenemase production is based on the susceptibility of these enzymes to boronic acid and boronic acid derivatives, i.e., phenylboronic and 3-aminophenylboronic acid (PBA). For MBL detection, DDST, CDT and carbapenemase PBA-impregnated agar techniques are used.

PBA and PBA-combined discs are prepared as previously described[173]. To prepare PBA-impregnated agar, 750 µL of PBA at 10 mg/mL is spread onto a Mueller Hinton agar plate[172].

Because boronic acid derivatives also inhibit AmpC-type β-lactamases, the simultaneous use of cloxacillin, which only inhibits AmpC but not class A enzymes, enhances the specificity of these tests. MH agar containing cloxacillin and discs containing boronic acid alone or meropenem in combination with boronic acid or cloxacillin are also commercially available (MAST, United Kingdom; Rosco, Denmark).

Notably, isolates with both KPC and MLB enzymes might not show synergy in inhibitor-based assays and appear highly resistant to carbapenems.

***Detection of OXA-48 based on temocillin-resistance***

CLSI and EUCAST interpretative criteria exhibit poor sensitivity in the detection of OXA-48 producers. The zone diameters for meropenem in OXA-48-producers can be up to 26 mm, thus < 27 mm must be used as a screening cut-off in countries where OXA-48 is endemic, at the expense of lower specificity[149].

Because OXA-48 carbapenemases confer high-level temocillin resistance, a disc diffusion assay using discs containing 30 µg of temocillin provides a reliable phenotypic test for the detection of OXA-48 in *Enterobacteriaceae*[174].

The combination of both temocillin and piperacillin/tazobactam diameters, < 12 mm and < 16 mm, respectively, is used to identify OXA-48 *Enterobacteriaceae* producers with high sensitivity and specificity[175].

***Detection using chromogenic media***

Several selective chromogenic media, in which species are distinguished according to colony color, are commercially available.

CHROMagar-KPC medium lacks sensitivity, as this medium only detects carbapenemase producers resistant to high levels of carbapenems. Thus, the detection of low-level resistance, as observed with KPC, IMP, VIM, NDM, and OXA-48, might not be achieved using this medium.

Supercarba medium is a Drigalski agar-based culture medium containing a low concentration of ertapenem, cloxacillin to prevent the growth of non-carbapenemase-producing carbapenem-resistant isolates, and zinc sulfate to improve the expression of MBLs. This medium might be used for the detection of not only KPC and MBL producers but also OXA-48 producers that do not co-express ESBLs. Supercarba medium exhibits higher sensitivity and specificity than other media and is useful for the specific selection of carbapenemase-producers in stools, as this medium inhibits the growth of ESBL producers.

CHROMagar-KPC and Supercarba medium are only suitable for *Enterobacteriaceae* testingbecausenon-enterobacterial non-carbapenemase-producing Gram-negative rods grow on these media[176].

ChromID CARBA is also designed for the specific detection of carbapenemase-producing *Enterobacteriaceae*, and the sensitivity and specificity of this medium is high. ChromID CARBA inhibits all ESBL producers and has demonstrated the excellent detection of CPE, with MICs from 2 to > 32 mg/L, however OXA-48 was only detected at a high inoculum (107 CFU/mL)[177].

Oxoid Brilliance CRE Agar exhibits high sensitivity for the detection of KPC and MBL-producing *Enterobacteriaceae*, but lower sensitivity if observed for the detection of OXA-48 producers. The specificity of this agar is relatively low, reflecting the growth of AmpC and ESBL producers that require further confirmation[178].

ChromID CARBA SMART is a new bi-plate combining two chromogenic media to rapidly and reliably identify all carbapenemase-producing *Enterobacteriaceae*, particularly KPC, NDM-1 and OXA-48; however, this medium has not yet been evaluated[179].

***Molecular detection of carbapenemase genes***

Molecular techniques, primarily based on PCR, are considered the reference standard for the identification and differentiation of carbapenem resistance genes based on the excellent specificity, sensitivity, accuracy and rapidity of these methods. If identification of a carbapenemase is required for epidemiological purposes, then the PCR products are subjected to additional sequencing. These techniques generate results within 4-6 h, or even less when real-time PCR techniques are used. The main disadvantages to the use of these techniques are high costs, requirement of trained technicians, and inability to detect novel carbapenemase genes.

Simplex PCR assays, using various primers and several in-house and commercial multiplex PCR tests, facilitate the simultaneous identification of multiple carbapenemase types[4,180,181], but the development of methods that further shorten the detection time, such as real-time systems, is needed[182,183].

The Xpert MDRO assay (Cepheid, Sunnyvale, CA) uses GeneXpert cartridges for the detection of carbapenemase-producing Gram-negative bacterial colonization directly from rectal swab samples in 47 min[184].

For the detection of the main carbapenemase gene types, PCR and hybridization-based kits, such as Hyplex MBL ID and Hyplex CarbOxa ID kits (BAG Health Care, Lich, Germany), are commercially available.

Microarray technology facilitates the rapid and reliable identification of multiple resistance determinants. Check-KPC ESBL and Check-MDR CT102 microarray analyses (Check-Points Health BV, Wageningen, Netherlands) have been successfully used for the detection of most clinically relevant carbapenemases within a single reaction[185].

***Spectrometry***

Spectrometry is based on a reduction in imipenem absorbance in the presence of carbapenemase-containing extracts of bacterial enzymes at a wavelength of 297 nm. This extract is obtained from an overnight culture of the isolate through mechanical lysis using sonication. Spectrometry accurately differentiates between carbapenemase producers and carbapenem-resistant bacteria with non-carbapenemase-mediated resistance mechanisms. Moreover, this method is cheap compared with molecular techniques and has excellent sensitivity and specificity (100% and 98.5%, respectively). However, spectrometry does not discriminate between different types of carbapenemases, is time-consuming and requires trained microbiologists[186]. Therefore, this technique is considered a reference method for the confirmation of carbapenemase activity: however, spectrometry is laborious and technically demanding, which limits the use of this method in reference laboratories.

***Matrix-assisted laser desorption ionization-time of flight mass spectrometry***

Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) is based on the detection of enzyme activity through the direct detection of hydrolysis degradation products, which show a different molecular mass from that of the native molecules[187].

Antibiotics and their degradation products are typically small molecules (< 1000 Da), making the analysis of these compounds difficult because the matrix is also visible in mass spectra and produces interference with high background levels. Thus, for the detection of these molecules, different matrices and modified approaches for sample preparation have been described[188,189].

The MALDI-TOF methodology involves the suspension of a fresh bacterial culture in a buffer, followed by centrifugation. The pellet is subsequently re-suspended in a reaction buffer containing carbapenem. After 1-3 h of incubation at 35 ºC, the reaction mixture is centrifuged, and the supernatant containing carbapenem and carbapenem metabolites is assessed through MALDI-TOF. Carbapenem activity is determined based on the disappearance of the peak corresponding to native carbapenem and the appearance of peaks corresponding to metabolites as a result of carbapenem hydrolysis[190]. All reported studies have presented similar results, demonstrating the excellent sensitivity and specificity for all carbapenemases, including OXA-type carbapenemases in *Enterobacteriaceae* and *Acinetobacter baumannii*[191,192].

Manual measurements and analyses of raw spectra, however, can be difficult and require trained microbiologists. Therefore, the availability of software for the automatic acquisition and interpretation of results is desirable in diagnostic laboratories.

The direct detection of carbapenemase activity from positive blood culture is currently being evaluated, having achieved adequate sensitivity[193].

**FIGHTING CARBAPENEMASES**

The fight against carbapenemase-producing bacteria should be based on three pillars: preventing transmission, avoiding antimicrobial selective pressure and developing new treatments.

Preventing transmission is presently the starting point to win this war. Therapeutic options are limited, particularly for NDM and KPC producers, making prevention the best strategy to avoid life-threatening infections, prolonged hospital stays and increased health care costs[146].

The first step in the prevention of transmission is to emphasize adherence to hand hygiene and standard precautions in daily clinical practice. In addition, the early identification of carriers is needed to apply control measures. Early detection can be achieved passively, selecting potential carriers through risk factor evaluation, or actively, through microbiological screening techniques.

The risk factors for carbapenem-producers are similar to those other multi-drug-resistant bacteria (MDR), including hospitalization, critical illness, surgery, ICU stays, the use of invasive devices and prior exposure to antimicrobial treatments. Recent travel to endemic countries is also important, particularly for medical tourism and military conflicts[194-196].

The active screening of patients is the gold standard to identify carriers. The number and type of patients investigated, the use of cultures, biochemical or molecular tests, and the duration of the surveillance program will depend on the economical characteristics of the country and whether the infection represents an outbreak event or an endemic situation[146].

Once the carriers have been identified, contact precautions and pre-emptive contact isolation must follow. Additionally, environmental decontamination and patient decolonization are recommended[129,197].

Antimicrobial stewardship to avoid antimicrobial selective pressure should be mandatory in sanitary institutions. Antimicrobials act as selectors and accelerators of diversity in resistance mechanisms, promoting MDR and selecting new resistance enzymes[78,198]. Thus, the high prevalence of ESBL-carriers in India encouraged the use of carbapenems as empirical treatment and selected carbapenemase-producers[199]. Nevertheless, this issue is controversial and more research is needed[146].

Finally, the third and most important pillar for clinical use against carbapenemase producers involves the development of new molecules that are either active against these pathogens or act as inhibitors of carbapenemases, which might extend the life of existing antimicrobials.

New antimicrobials are being developed to fight MDR. Sulfactams are monocyclic β-lactams structuraly related to monobactams, such as BAL30072, which exhibit potent activity against MDRs, particularly when combined with colistin or meropenem[200]. Plazomizin is a new-generation aminoglycoside with bactericidal effects on carbapenem-resistant bacteria, although more studies are needed to assess the activity of this antimicrobial[201,202]. TP-434 and GSK2251052 are antimicrobials that target protein synthesis and exhibit a spectrum encompassing multidrug-resistant Gram-negative pathogens[203].

Moreover, carbapenemase inhibitors have also been developed, including Penem derivatives, such as BRL 42715, which inhibit serine β-lactamases, and BLI-489, which inhibits KPC; 1-β-methylcarbapenem compounds, such as J-110,411 and J-11,225, which inhibit classes A and C and IMP-type enzymes; Thiols, such as thiomandelic acids, which inhibit MBLs; and avibactam, which inhibits serine β-lactamases. These compounds will likely extend the life and increase the activity of existing antimicrobials and bring hope in the carbapenemase era[19,204].

**CONCLUDING REMARKS**

Carbapenem-resistant bacteria, particularly *Enterobacteriaceae*, *Pseudomonas* and *Acinetobacter*, have become a challenging health issue worldwide. Fourteen years have passed since Livermore et al. published the article entitled “Carbapenemases: a problem in waiting?”[205]. These authors discussed the emergence of new carbapenem-hydrolyzing enzymes and the possibility that these molecules could pose a threat to infection treatment in the near future. Five years later, Walsh et al. warned about the perils of MBLs, remarking on the spread of these enzymes through horizontal gene transfer and resistance mechanisms to other antimicrobial families[206]. These authors suggested the development of both surveillance programs and new inhibitors.

Moreover, in 2012, Nordmann *et al*[207] published an article entitled “Carbapenem resistance in *Enterobacteriaceae*: here is the storm!”, stating that carbapenemase-producing *Enterobacteriaceae* constituted a growing threat to public health[207].

To paraphrase John Donne, “no man is an island”, in this case “no country is an island”. Thus, now that the storm has arrived, international organizations, such as the WHO, CDC and ECDC, have called for a worldwide collaboration to contain this epidemic[146]. Migration fluxes, vacations and medical travels or distant military conflicts likely contribute to the spread of resistance genes across the globe, and only through a collaborative global effort, will we successfully address this problem.

**REFERENCES**

1 **Bush K**, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother* 1995; **39**: 1211-1233 [PMID: 7574506 DOI: 10.1128/AAC.39.6.1211]

2 **Bush K**, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 2010; **54**: 969-976 [PMID: 19995920 DOI: 10.1128/AAC.01009-09]

3 **Ambler RP**. The structure of beta-lactamases. *Philos Trans R Soc Lond B Biol Sci* 1980; **289**: 321-331 [PMID: 6109327 DOI: 10.1098/rstb.1980.0049]

4 **Queenan AM**, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev* 2007; **20**: 440-58, table of contents [PMID: 17630334 DOI: 10.1128/CMR.00001-07]

5 **Medeiros AA**, Hare RS. β-Lactamase-mediated resistance to penems and carbapenems amongst Enterobacteriaceae, abstract 116. 26th Intersci Conf Antimicrob Agents Chemother 1986. American Society for Microbiology, Washington, DC, 1986

6 **Nordmann P**, Mariotte S, Naas T, Labia R, Nicolas MH. Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. *Antimicrob Agents Chemother* 1993; **37**: 939-946 [PMID: 8517720 DOI: 10.1128/AAC.37.5.939]

7 **Yang YJ**, Wu PJ, Livermore DM. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. *Antimicrob Agents Chemother* 1990; **34**: 755-758 [PMID: 2193618 DOI: 10.1128/AAC.34.5.755]

8 **Petrella S**, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. *Antimicrob Agents Chemother* 2008; **52**: 3725-3736 [PMID: 18625772 DOI: 10.1128/AAC.00163-08]

9 **Naas T**, Nordmann P. Analysis of a carbapenem-hydrolyzing class A beta-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein. *Proc Natl Acad Sci U S A* 1994; **91**: 7693-7697 [PMID: 8052644]

10 **Rasmussen BA**, Bush K, Keeney D, Yang Y, Hare R, O'Gara C, Medeiros AA. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. *Antimicrob Agents Chemother* 1996; **40**: 2080-2086 [PMID: 8878585]

11 **Queenan AM**, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. *Antimicrob Agents Chemother* 2006; **50**: 3485-3487 [PMID: 17005839 DOI: 10.1128/AAC.00363-06]

12 **Yigit H**, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. *Antimicrob Agents Chemother* 2001; **45**: 1151-1161 [PMID: 11257029 DOI: 10.1128/AAC.45.4.1151-1161.2001]

13 **Navon-Venezia S**, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. *Antimicrob Agents Chemother* 2006; **50**: 3098-3101 [PMID: 16940107 DOI: 10.1128/AAC.00438-06]

14 **Villegas MV**, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. *Antimicrob Agents Chemother* 2007; **51**: 1553-1555 [PMID: 17261621 DOI: 10.1128/AAC.01405-06]

15 **Bratu S**, Brooks S, Burney S, Kochar S, Gupta J, Landman D, Quale J. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. *Clin Infect Dis* 2007; **44**: 972-975 [PMID: 17342651 DOI: 10.1086/512370]

16 **Miriagou V**, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. *Antimicrob Agents Chemother* 2003; **47**: 1297-1300 [PMID: 12654661 DOI: 10.1128/AAC.47.4.1297-1300.2003]

17 **Hossain A**, Ferraro MJ, Pino RM, Dew RB, Moland ES, Lockhart TJ, Thomson KS, Goering RV, Hanson ND. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. *Antimicrob Agents Chemother* 2004; **48**: 4438-4440 [PMID: 15504876 DOI: 10.1128/AAC.48.11.4438-4440.2004]

18 **Walther-Rasmussen J**, Høiby N. Class A carbapenemases. *J Antimicrob Chemother* 2007; **60**: 470-482 [PMID: 17595289 DOI: 10.1093/jac/dkm226]

19 **Tzouvelekis LS**, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clin Microbiol Rev* 2012; **25**: 682-707 [PMID: 23034326 DOI: 10.1128/CMR.05035-11]

20 **Poirel L**, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. *J Antimicrob Chemother* 2012; **67**: 1597-1606 [PMID: 22499996 DOI: 10.1093/jac/dks121]

21 **Evans BA**, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. *Curr Pharm Des* 2013; **19**: 223-238 [PMID: 22894617 DOI: 10.2174/138161213804070285]

22 **Zhao WH**, Hu ZQ. Acinetobacter: a potential reservoir and dispenser for β-lactamases. *Crit Rev Microbiol* 2012; **38**: 30-51 [PMID: 22007992 DOI: 10.3109/1040841X.2011.621064]

23 **Cuzon G**, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. *Antimicrob Agents Chemother* 2011; **55**: 2420-2423 [PMID: 21343451 DOI: 10.1128/AAC.01452-10]

24 **Giani T**, Conte V, Di Pilato V, Aschbacher R, Weber C, Larcher C, Rossolini GM. Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. *Antimicrob Agents Chemother* 2012; **56**: 2211-2213 [PMID: 22290939 DOI: 10.1128/AAC.00035-12]

25 **Glupczynski Y**, Huang TD, Bouchahrouf W, Rezende de Castro R, Bauraing C, Gérard M, Verbruggen AM, Deplano A, Denis O, Bogaerts P. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. *Int J Antimicrob Agents* 2012; **39**: 168-172 [PMID: 22115539 DOI: 10.1016/j.ijantimicag.2011.10.005]

26 **Kilic A**, Aktas Z, Bedir O, Gumral R, Bulut Y, Stratton C, Tang YW, Basustaoglu AC. Identification and characterization of OXA-48 producing, carbapenem-resistant Enterobacteriaceae isolates in Turkey. *Ann Clin Lab Sci* 2011; **41**: 161-166 [PMID: 21844575]

27 **Poirel L**, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. *Antimicrob Agents Chemother* 2004; **48**: 15-22 [PMID: 14693513 DOI: 10.1128/AAC.48.1.15-22.2004]

28 **Kim JY**, Jung HI, An YJ, Lee JH, Kim SJ, Jeong SH, Lee KJ, Suh PG, Lee HS, Lee SH, Cha SS. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase. *Mol Microbiol* 2006; **60**: 907-916 [PMID: 16677302 DOI: 10.1111/j.1365-2958.2006.05146.x]

29 **Palzkill T**. Metallo-β-lactamase structure and function. *Ann N Y Acad Sci* 2013; **1277**: 91-104 [PMID: 23163348 DOI: 10.1111/j.1749-6632.2012.06796.x]

30 **Cornaglia G**, Akova M, Amicosante G, Cantón R, Cauda R, Docquier JD, Edelstein M, Frère JM, Fuzi M, Galleni M, Giamarellou H, Gniadkowski M, Koncan R, Libisch B, Luzzaro F, Miriagou V, Navarro F, Nordmann P, Pagani L, Peixe L, Poirel L, Souli M, Tacconelli E, Vatopoulos A, Rossolini GM. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. *Int J Antimicrob Agents* 2007; **29**: 380-388 [PMID: 17223319 DOI: 10.1016/j.ijantimicag.2006.10.008]

31 **Kuwabara S**, Abraham EP. Some properties of two extracellular beta-lactamases from Bacillus cereus 569/H. *Biochem J* 1967; **103**: 27C-30C [PMID: 4963457]

32 **Walsh TR**, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005; **18**: 306-325 [PMID: 15831827 DOI: 10.1128/CMR.18.2.306-325.2005]

33 **Rossolini GM**. Acquired metallo-beta-lactamases: an increasing clinical threat. *Clin Infect Dis* 2005; **41**: 1557-1558 [PMID: 16267726 DOI: 10.1086/497839]

34 **Cornaglia G**, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams? *Lancet Infect Dis* 2011; **11**: 381-393 [PMID: 21530894 DOI: 10.1016/S1473-3099(11)70056-1]

35 **Rolain JM**, Parola P, Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia? *Clin Microbiol Infect* 2010; **16**: 1699-1701 [PMID: 20874758 DOI: 10.1111/j.1469-0691.2010.03385.x]

36 **Kumarasamy KK**, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010; **10**: 597-602 [PMID: 20705517 DOI: 10.1016/S1473-3099(10)70143-2]

37 **Karthikeyan K**, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. *J Antimicrob Chemother* 2010; **65**: 2253-2254 [PMID: 20650909 DOI: 10.1093/jac/dkq273]

38 **Nordmann P**, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. *Clin Microbiol Infect* 2014; **20**: 821-830 [PMID: 24930781 DOI: 10.1111/1469-0691.12719]

39 **Osano E**, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, Yoshimura F, Kato N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. *Antimicrob Agents Chemother* 1994; **38**: 71-78 [PMID: 8141584 DOI: 10.1128/AAC.38.1.71]

40 **Miriagou V**, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, Malamou-Lada E, Martinez-Martinez L, Navarro F, Nordmann P, Peixe L, Pournaras S, Rossolini GM, Tsakris A, Vatopoulos A, Cantón R. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. *Clin Microbiol Infect* 2010; **16**: 112-122 [PMID: 20085605 DOI: 10.1111/j.1469-0691.2009.03116.x]

41 **Lauretti L**, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. *Antimicrob Agents Chemother* 1999; **43**: 1584-1590 [PMID: 10390207]

42 **Toleman MA**, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN, Walsh TR. Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. *J Antimicrob Chemother* 2002; **50**: 673-679 [PMID: 12407123 DOI: 10.1093/jac/dkf210]

43 **Murphy TA**, Simm AM, Toleman MA, Jones RN, Walsh TR. Biochemical characterization of the acquired metallo-beta-lactamase SPM-1 from Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2003; **47**: 582-587 [PMID: 12543663 DOI: 10.1128/AAC.47.2.582-587.2003]

44 **Hamprecht A**, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. *J Antimicrob Chemother* 2013; **68**: 558-561 [PMID: 23152484 DOI: 10.1093/jac/dks447]

45 **Fisher JF**, Mobashery S. Three decades of the class A beta-lactamase acyl-enzyme. *Curr Protein Pept Sci* 2009; **10**: 401-407 [PMID: 19538154]

46 **Hata M**, Fujii Y, Tanaka Y, Ishikawa H, Ishii M, Neya S, Tsuda M, Hoshino T. Substrate deacylation mechanisms of serine-beta-lactamases. *Biol Pharm Bull* 2006; **29**: 2151-2159 [PMID: 17077507]

47 **Fujii Y,** Hata M, Hoshino T, Tsuda M. Catalytic mechanism of Class A ß-Lactamase: Role of Lysine 73 and C3-carboxyl group of the substrate penicilin G in the deacylation step. *J Phys Chem B* 2002; **106**: 9687-9695 [DOI: 10.1021/jp021414c]

48 **Ke W**, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. *Biochemistry* 2007; **46**: 5732-5740 [PMID: 17441734 DOI: 10.1021/bi700300u]

49 **Frase H**, Shi Q, Testero SA, Mobashery S, Vakulenko SB. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases. *J Biol Chem* 2009; **284**: 29509-29513 [PMID: 19656947]

50 **Frase H**, Toth M, Champion MM, Antunes NT, Vakulenko SB. Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid. *Antimicrob Agents Chemother* 2011; **55**: 1556-1562 [PMID: 21220532 DOI: 10.1128/AAC.01292-10]

51 **Smith CA**, Caccamo M, Kantardjieff KA, Vakulenko S. Structure of GES-1 at atomic resolution: insights into the evolution of carbapenamase activity in the class A extended-spectrum beta-lactamases. *Acta Crystallogr D Biol Crystallogr* 2007; **63**: 982-992 [PMID: 17704567 DOI: 10.1107/S0907444907036955]

52 **Poirel L**, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. *Antimicrob Agents Chemother* 2001; **45**: 2598-2603 [PMID: 11502535]

53 **Majiduddin FK**, Palzkill T. Amino acid residues that contribute to substrate specificity of class A beta-lactamase SME-1. *Antimicrob Agents Chemother* 2005; **49**: 3421-3427 [PMID: 16048956 DOI: 10.1128/AAC.49.8.3421-3427.2005]

54 **Sougakoff W**, Naas T, Nordmann P, Collatz E, Jarlier V. Role of ser-237 in the substrate specificity of the carbapenem-hydrolyzing class A beta-lactamase Sme-1. *Biochim Biophys Acta* 1999; **1433**: 153-158 [PMID: 10446368]

55 **Woodford N**, Tierno PM, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J, Livermore DM. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. *Antimicrob Agents Chemother* 2004; **48**: 4793-4799 [PMID: 15561858 DOI: 10.1128/AAC.48.12.4793-4799.2004]

56 **Golemi D**, Maveyraud L, Vakulenko S, Samama JP, Mobashery S. Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. *Proc Natl Acad Sci U S A* 2001; **98**: 14280-14285 [PMID: 11724923 DOI: 10.1073/pnas.241442898]

57 **Fisher JF**, Meroueh SO, Mobashery S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. *Chem Rev* 2005; **105**: 395-424 [PMID: 15700950 DOI: 10.1021/cr030102i]

58 **Leonard DA**, Bonomo RA, Powers RA. Class D β-lactamases: a reappraisal after five decades. *Acc Chem Res* 2013; **46**: 2407-2415 [PMID: 23902256 DOI: 10.1021/ar300327a]

59 **Szarecka A**, Lesnock KR, Ramirez-Mondragon CA, Nicholas HB, Wymore T. The Class D beta-lactamase family: residues governing the maintenance and diversity of function. *Protein Eng Des Sel* 2011; **24**: 801-809 [PMID: 21859796 DOI: 10.1093/protein/gzr041]

60 **Danel F**, Paetzel M, Strynadka NC, Page MG. Effect of divalent metal cations on the dimerization of OXA-10 and -14 class D beta-lactamases from Pseudomonas aeruginosa. *Biochemistry* 2001; **40**: 9412-9420 [PMID: 11478911]

61 **Frère JM**, Dubus A, Galleni M, Matagne A, Amicosante G. Mechanistic diversity of beta-lactamases. *Biochem Soc Trans* 1999; **27**: 58-63 [PMID: 10093707]

62 **Paetzel M**, Danel F, de Castro L, Mosimann SC, Page MG, Strynadka NC. Crystal structure of the class D beta-lactamase OXA-10. *Nat Struct Biol* 2000; **7**: 918-925 [PMID: 11017203 DOI: 10.1038/79688]

63 **Schneider KD**, Bethel CR, Distler AM, Hujer AM, Bonomo RA, Leonard DA. Mutation of the active site carboxy-lysine (K70) of OXA-1 beta-lactamase results in a deacylation-deficient enzyme. *Biochemistry* 2009; **48**: 6136-6145 [PMID: 19485421 DOI: 10.1021/bi900448u]

64 **Santillana E**, Beceiro A, Bou G, Romero A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. *Proc Natl Acad Sci U S A* 2007; **104**: 5354-5359 [PMID: 17374723 DOI: 10.1073/pnas.0607557104]

65 **Docquier JD**, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L, Tafi A, Nordmann P, Botta M, Rossolini GM, Mangani S. Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. *Chem Biol* 2009; **16**: 540-547 [PMID: 19477418 DOI: 10.1016/j.chembiol.2009.04.010]

66 **De Luca F**, Benvenuti M, Carboni F, Pozzi C, Rossolini GM, Mangani S, Docquier JD. Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. *Proc Natl Acad Sci U S A* 2011; **108**: 18424-18429 [PMID: 22042844 DOI: 10.1073/pnas.1110530108]

67 **Verma V**, Testero SA, Amini K, Wei W, Liu J, Balachandran N, Monoharan T, Stynes S, Kotra LP, Golemi-Kotra D. Hydrolytic mechanism of OXA-58 enzyme, a carbapenem-hydrolyzing class D β-lactamase from Acinetobacter baumannii. *J Biol Chem* 2011; **286**: 37292-37303 [PMID: 21880707 DOI: 10.1074/jbc.M111.280115]

68 **Fitzgerald PM**, Wu JK, Toney JH. Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution. *Biochemistry* 1998; **37**: 6791-6800 [PMID: 9578564 DOI: 10.1021/bi9730339]

69 **Murphy TA**, Catto LE, Halford SE, Hadfield AT, Minor W, Walsh TR, Spencer J. Crystal structure of Pseudomonas aeruginosa SPM-1 provides insights into variable zinc affinity of metallo-beta-lactamases. *J Mol Biol* 2006; **357**: 890-903 [PMID: 16460758 DOI: 10.1016/j.jmb.2006.01.003]

70 **Carfi A**, Duée E, Galleni M, Frère JM, Dideberg O. 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. *Acta Crystallogr D Biol Crystallogr* 1998; **54**: 313-323 [PMID: 9761898]

71 **Page MI**, Badarau A. The mechanisms of catalysis by metallo beta-lactamases. *Bioinorg Chem Appl* 2008: 576297 [PMID: 18551183 DOI: 10.1155/2008/576297]

72 **Niguel P**, Gensmantel, Proctor P, Page MI. Metal-Ion catalysed hydrolysis of some small beta-lactam antibiotics. *J Chem Soc*, Perkin Transactions 1980; **2**: 1725-1732 [DOI: 10.1039/P29800001725]

73 **Carfi A**, Pares S, Duée E, Galleni M, Duez C, Frère JM, Dideberg O. The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. *EMBO J* 1995; **14**: 4914-4921 [PMID: 7588620]

74 **Concha NO**, Rasmussen BA, Bush K, Herzberg O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. *Structure* 1996; **4**: 823-836 [PMID: 8805566]

75 **Garau G**, Bebrone C, Anne C, Galleni M, Frère JM, Dideberg O. A metallo-beta-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. *J Mol Biol* 2005; **345**: 785-795 [PMID: 15588826 DOI: 10.1016/j.jmb.2004.10.070]

76 **Yim G**, Wang HH, Davies J. Antibiotics as signalling molecules. *Philos Trans R Soc Lond B Biol Sci* 2007; **362**: 1195-1200 [PMID: 17360275 DOI: 10.1098/rstb.2007.2044]

77 **Massova I**, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. *Antimicrob Agents Chemother* 1998; **42**: 1-17 [PMID: 9449253 DOI: 10.1093/jac/42.1.1]

78 **Galán JC**, González-Candelas F, Rolain JM, Cantón R. Antibiotics as selectors and accelerators of diversity in the mechanisms of resistance: from the resistome to genetic plasticity in the β-lactamases world. *Front Microbiol* 2013; **4**: 9 [PMID: 23404545 DOI: 10.3389/fmicb.2013.00009]

79 **Dantas G**, Sommer MO. Context matters - the complex interplay between resistome genotypes and resistance phenotypes. *Curr Opin Microbiol* 2012; **15**: 577-582 [PMID: 22954750 DOI: 10.1016/j.mib.2012.07.004]

80 **Pehrsson EC**, Forsberg KJ, Gibson MK, Ahmadi S, Dantas G. Novel resistance functions uncovered using functional metagenomic investigations of resistance reservoirs. *Front Microbiol* 2013; **4**: 145 [PMID: 23760651 DOI: 10.3389/fmicb.2013.00145]

81 **Raz Y**, Tannenbaum E. The influence of horizontal gene transfer on the mean fitness of unicellular populations in static environments. *Genetics* 2010; **185**: 327-337 [PMID: 20194966 DOI: 10.1534/genetics.109.113613]

82 **Bulychev A**, Massova I, Miyashita K, Mobashery S. Nuances of mechanisms and their implications for evolution of the versatile b-lactam hydrolase activity: from biosynthetic enzymes to drug resistance factors. *J Am Chem Soc* 1997; **119**: 7619–7625 [DOI: 10.1021/ja963708f]

83 **Ghuysen JM**. Penicillin-binding proteins. Wall peptidoglycan assembly and resistance to penicillin: facts, doubts and hopes. *Int J Antimicrob Agents* 1997; **8**: 45-60 [PMID: 18611784 DOI: 10.1016/S0924-8579(96)00358-5]

84 **Urbach C**, Fastrez J, Soumillion P. A new family of cyanobacterial penicillin-binding proteins. A missing link in the evolution of class A beta-lactamases. *J Biol Chem* 2008; **283**: 32516-32526 [PMID: 18801739 DOI: 10.1074/jbc.M805375200]

85 **Hall BG**, Barlow M. Structure-based phylogenies of the serine beta-lactamases. *J Mol Evol* 2003; **57**: 255-260 [PMID: 14629035 DOI: 10.1007/s00239-003-2473-y]

86 **Hall BG**, Barlow M. Evolution of the serine beta-lactamases: past, present and future. *Drug Resist Updat* 2004; **7**: 111-123 [PMID: 15158767 DOI: 10.1016/s1368-7646(04)00018-4]

87 **Haeggman S**, Löfdahl S, Paauw A, Verhoef J, Brisse S. Diversity and evolution of the class A chromosomal beta-lactamase gene in Klebsiella pneumoniae. *Antimicrob Agents Chemother* 2004; **48**: 2400-2408 [PMID: 15215087 DOI: 10.1128/AAC.48.7.2400-2408]

88 **Paton R**, Miles RS, Hood J, Amyes SG, Miles RS, Amyes SG. ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. *Int J Antimicrob Agents* 1993; **2**: 81-87 [PMID: 18611526 DOI: 10.1016/0924-8579(93)90045-7]

89 **Héritier C**, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. *Antimicrob Agents Chemother* 2005; **49**: 4174-4179 [PMID: 16189095 DOI: 10.1128/AAC.49.10.4174-4179]

90 **Potron A**, Poirel L, Nordmann P. Origin of OXA-181, an emerging carbapenem-hydrolyzing oxacillinase, as a chromosomal gene in Shewanella xiamenensis. *Antimicrob Agents Chemother* 2011; **55**: 4405-4407 [PMID: 21746953 DOI: 10.1128/AAC.00681-11]

91 **Zong Z**. Discovery of bla(OXA-199), a chromosome-based bla(OXA-48)-like variant, in Shewanella xiamenensis. *PLoS One* 2012; **7**: e48280 [PMID: 23110226 DOI: 10.1371/journal.pone.0048280]

92 **Poirel L**, Héritier C, Nordmann P. Chromosome-encoded ambler class D beta-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. *Antimicrob Agents Chemother* 2004; **48**: 348-351 [PMID: 14693565 DOI: 10.1128/AAC.48.1.348-351]

93 **Lascols C**, Podglajen I, Verdet C, Gautier V, Gutmann L, Soussy CJ, Collatz E, Cambau E. A plasmid-borne Shewanella algae Gene, qnrA3, and its possible transfer in vivo between Kluyvera ascorbata and Klebsiella pneumoniae. *J Bacteriol* 2008; **190**: 5217-5223 [PMID: 18515416 DOI: 10.1128/JB.00243-08]

94 **Garau G**, Di Guilmi AM, Hall BG. Structure-based phylogeny of the metallo-beta-lactamases. *Antimicrob Agents Chemother* 2005; **49**: 2778-2784 [PMID: 15980349 DOI: 10.1128/AAC.49.7.2778-2784.2005]

95 **Hall BG**, Salipante SJ, Barlow M. The metallo-beta-lactamases fall into two distinct phylogenetic groups. *J Mol Evol* 2003; **57**: 249-254 [PMID: 14629034 DOI: 10.1007/s00239-003-2471-0]

96 **Karlin S**, Brocchieri L, Mrázek J, Kaiser D. Distinguishing features of delta-proteobacterial genomes. *Proc Natl Acad Sci U S A* 2006; **103**: 11352-11357 [PMID: 16844781]

97 **Stoczko M**, Frère JM, Rossolini GM, Docquier JD. Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. *Antimicrob Agents Chemother* 2008; **52**: 2473-2479 [PMID: 18443127 DOI: 10.1128/AAC.01062-07]

98 **Sekizuka T**, Matsui M, Yamane K, Takeuchi F, Ohnishi M, Hishinuma A, Arakawa Y, Kuroda M. Complete sequencing of the bla(NDM-1)-positive IncA/C plasmid from Escherichia coli ST38 isolate suggests a possible origin from plant pathogens. *PLoS One* 2011; **6**: e25334 [PMID: 21966500 DOI: 10.1371/journal.pone.0025334]

99 **Marchiaro PM**, Brambilla L, Morán-Barrio J, Revale S, Pasteran F, Vila AJ, Viale AM, Limansky AS. The complete nucleotide sequence of the carbapenem resistance-conferring conjugative plasmid pLD209 from a Pseudomonas putida clinical strain reveals a chimeric design formed by modules derived from both environmental and clinical bacteria. *Antimicrob Agents Chemother* 2014; **58**: 1816-1821 [PMID: 24395220 DOI: 10.1128/AAC.02494-13]

100 **Segawa T**, Takeuchi N, Rivera A, Yamada A, Yoshimura Y, Barcaza G, Shinbori K, Motoyama H, Kohshima S, Ushida K. Distribution of antibiotic resistance genes in glacier environments. *Environ Microbiol Rep* 2013; **5**: 127-134 [PMID: 23757141 DOI: 10.1111/1758-2229.12011]

101 **Nordmann P**, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2011; **17**: 1791-1798 [PMID: 22000347 DOI: 10.3201/eid1710.110655]

102 **Cuzon G**, Naas T, Nordmann P. Functional characterization of Tn4401, a Tn3-based transposon involved in blaKPC gene mobilization. *Antimicrob Agents Chemother* 2011; **55**: 5370-5373 [PMID: 21844325 DOI: 10.1128/AAC.05202-11]

103 **Luo Y**, Yang J, Ye L, Guo L, Zhao Q, Chen R, Chen Y, Han X, Zhao J, Tian S, Han L. Characterization of KPC-2-producing Escherichia coli, Citrobacter freundii, Enterobacter cloacae, Enterobacter aerogenes, and Klebsiella oxytoca isolates from a Chinese Hospital. *Microb Drug Resist* 2014; **20**: 264-269 [PMID: 24433026 DOI: 10.1089/mdr.2013.0150]

104 **Bryant KA**, Van Schooneveld TC, Thapa I, Bastola D, Williams LO, Safranek TJ, Hinrichs SH, Rupp ME, Fey PD. KPC-4 Is encoded within a truncated Tn4401 in an IncL/M plasmid, pNE1280, isolated from Enterobacter cloacae and Serratia marcescens. *Antimicrob Agents Chemother* 2013; **57**: 37-41 [PMID: 23070154 DOI: 10.1128/AAC.01062-12]

105 **Naas T**, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. *Antimicrob Agents Chemother* 2008; **52**: 1257-1263 [PMID: 18227185 DOI: 10.1128/AAC.01451-07]

106 **Poirel L**, Carrër A, Pitout JD, Nordmann P. Integron mobilization unit as a source of mobility of antibiotic resistance genes. *Antimicrob Agents Chemother* 2009; **53**: 2492-2498 [PMID: 19332679 DOI: 10.1128/AAC.00033-09]

107 **Aubron C**, Poirel L, Ash RJ, Nordmann P. Carbapenemase-producing Enterobacteriaceae, U.S. rivers. *Emerg Infect Dis* 2005; **11**: 260-264 [PMID: 15752444 DOI: 10.3201/eid1102.030684]

108 **Yu YS**, Du XX, Zhou ZH, Chen YG, Li LJ. First isolation of blaIMI-2 in an Enterobacter cloacae clinical isolate from China. *Antimicrob Agents Chemother* 2006; **50**: 1610-1611 [PMID: 16569898 DOI: 10.1128/AAC.50.4.1610-1611]

109 **Walther-Rasmussen J**, Høiby N. OXA-type carbapenemases. *J Antimicrob Chemother* 2006; **57**: 373-383 [PMID: 16446375]

110 **Seputiene V**, Povilonis J, Suziedeliene E. Novel variants of AbaR resistance islands with a common backbone in Acinetobacter baumannii isolates of European clone II. *Antimicrob Agents Chemother* 2012; **56**: 1969-1973 [PMID: 22290980 DOI: 10.1128/AAC.05678-11]

111 **Beyrouthy R**, Robin F, Delmas J, Gibold L, Dalmasso G, Dabboussi F, Hamzé M, Bonnet R. IS1R-mediated plasticity of IncL/M plasmids leads to the insertion of bla OXA-48 into the Escherichia coli Chromosome. *Antimicrob Agents Chemother* 2014; **58**: 3785-3790 [PMID: 24752261 DOI: 10.1128/AAC.02669-14]

112 **Potron A**, Poirel L, Nordmann P. Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. *Antimicrob Agents Chemother* 2014; **58**: 467-471 [PMID: 24189247 DOI: 10.1128/AAC.01344-13]

113 **Peirano G**, Lascols C, Hackel M, Hoban DJ, Pitout JD. Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program. *Diagn Microbiol Infect Dis* 2014; **78**: 277-281 [PMID: 24387958 DOI: 10.1016/j.diagmicrobio.2013.11.024]

114 **Diene SM**, Rolain JM. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. *Clin Microbiol Infect* 2014; **20**: 831-838 [PMID: 24766097 DOI: 10.1111/1469-0691.12655]

115 **Yamamoto M**, Nagao M, Matsumura Y, Hotta G, Matsushima A, Ito Y, Takakura S, Ichiyama S. Regional dissemination of Acinetobacter species harbouring metallo-β-lactamase genes in Japan. *Clin Microbiol Infect* 2013; **19**: 729-736 [PMID: 23009350 DOI: 10.1111/1469-0691.12013]

116 **Bonnin RA**, Poirel L, Nordmann P. New Delhi metallo-β-lactamase-producing Acinetobacter baumannii: a novel paradigm for spreading antibiotic resistance genes. *Future Microbiol* 2014; **9**: 33-41 [PMID: 24328379 DOI: 10.2217/fmb.13.69]

117 **Yong D**, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. *Antimicrob Agents Chemother* 2009; **53**: 5046-5054 [PMID: 19770275 DOI: 10.1128/AAC.00774-09]

118 **Toleman MA**, Spencer J, Jones L, Walsh TR. blaNDM-1 is a chimera likely constructed in Acinetobacter baumannii. *Antimicrob Agents Chemother* 2012; **56**: 2773-2776 [PMID: 22314529 DOI: 10.1128/AAC.06297-11]

119 **Jones LS**, Toleman MA, Weeks JL, Howe RA, Walsh TR, Kumarasamy KK. Plasmid carriage of bla NDM-1 in clinical Acinetobacter baumannii isolates from India. *Antimicrob Agents Chemother* 2014; **58**: 4211-4213 [PMID: 24752257 DOI: 10.1128/AAC.02500-14]

120 **Partridge SR**, Iredell JR. Genetic contexts of blaNDM-1. *Antimicrob Agents Chemother* 2012; **56**: 6065-607; author reply 6071 [PMID: 23074228 DOI: 10.1128/AAC.00117-12]

121 **Dortet L**, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. *Biomed Res Int* 2014; **2014**: 249856 [PMID: 24790993 DOI: 10.1155/2014/249856]

122 **Janvier F**, Jeannot K, Tessé S, Robert-Nicoud M, Delacour H, Rapp C, Mérens A. Molecular characterization of blaNDM-1 in a sequence type 235 Pseudomonas aeruginosa isolate from France. *Antimicrob Agents Chemother* 2013; **57**: 3408-3411 [PMID: 23612200 DOI: 10.1128/AAC.02334-12]

123 **Song JS**, Jang SJ, Lee JJ, Lee JH, Bae IK, Jeong BC, Cha SS, Lee JH, Hong SK, Lee SH. Association of the bla(CMY-10) gene with a novel complex class 1 integron carrying an ISCR1 element in clinical isolates from Korea. *Clin Microbiol Infect* 2010; **16**: 1013-1017 [PMID: 19681956 DOI: 10.1111/j.1469-0691.2009.03002.x]

124 **Marciano DC**, Karkouti OY, Palzkill T. A fitness cost associated with the antibiotic resistance enzyme SME-1 beta-lactamase. *Genetics* 2007; **176**: 2381-2392 [PMID: 17565956 DOI: 10.1534/genetics.106.069443]

125 **Mataseje LF**, Boyd DA, Delport J, Hoang L, Imperial M, Lefebvre B, Kuhn M, Van Caeseele P, Willey BM, Mulvey MR. Serratia marcescens harbouring SME-type class A carbapenemases in Canada and the presence of blaSME on a novel genomic island, SmarGI1-1. *J Antimicrob Chemother* 2014; **69**: 1825-1829 [PMID: 24659751 DOI: 10.1093/jac/dku040]

126 **Österblad M**, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, Jalava J. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008-11). *J Antimicrob Chemother* 2012; **67**: 2860-2864 [PMID: 22855858 DOI: 10.1093/jac/dks299]

127 **Robledo IE**, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ. Detection of KPC in Acinetobacter spp. in Puerto Rico. *Antimicrob Agents Chemother* 2010; **54**: 1354-1357 [PMID: 20038618 DOI: 10.1128/AAC.00899-09]

128 **Cantón R**, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. *Clin Microbiol Infect* 2012; **18**: 413-431 [PMID: 22507109 DOI: 10.1111/j.1469-0691.2012.03821.x]

129 **Munoz-Price LS**, De La Cuesta C, Adams S, Wyckoff M, Cleary T, McCurdy SP, Huband MD, Lemmon MM, Lescoe M, Dibhajj FB, Hayden MK, Lolans K, Quinn JP. Successful eradication of a monoclonal strain of Klebsiella pneumoniae during a K. pneumoniae carbapenemase-producing K. pneumoniae outbreak in a surgical intensive care unit in Miami, Florida. *Infect Control Hosp Epidemiol* 2010; **31**: 1074-1077 [PMID: 20738186 DOI: 10.1086/656243]

130 **Leung V**, Loo VG, Frenette C, Domingo MC, Bourgault AM, Mulvey MR, Robson HG. First Canadian outbreak of Enterobacteriaceae-expressing Klebsiella pneumoniae carbapenemase type 3. *Can J Infect Dis Med Microbiol* 2012; **23**: 117-120 [PMID: 23997777]

131 **Girlich D**, Poirel L, Szczepanowski R, Schlüter A, Nordmann P. Carbapenem-hydrolyzing GES-5-encoding gene on different plasmid types recovered from a bacterial community in a sewage treatment plant. *Appl Environ Microbiol* 2012; **78**: 1292-1295 [PMID: 22156421 DOI: 10.1128/AEM.06841-11]

132 **Poirel L**, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. *Antimicrob Agents Chemother* 2010; **54**: 24-38 [PMID: 19721065 DOI: 10.1128/AAC.01512-08]

133 **Potron A**, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. *Clin Microbiol Infect* 2011; **17**: E24-E26 [PMID: 21973185 DOI: 10.1111/j.1469-0691.2011.03669.x]

134 **Watanabe M**, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 1991; **35**: 147-151 [PMID: 1901695]

135 **Tada T**, Miyoshi-Akiyama T, Shimada K, Shimojima M, Kirikae T. IMP-43 and IMP-44 metallo-β-lactamases with increased carbapenemase activities in multidrug-resistant Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2013; **57**: 4427-4432 [PMID: 23836174 DOI: 10.1128/AAC.00716-13]

136 **Chen S**, Feng W, Chen J, Liao W, He N, Wang Q, Sun F, Xia P. Spread of carbapenemase-producing enterobacteria in a southwest hospital in China. *Ann Clin Microbiol Antimicrob* 2014; **13**: 42 [PMID: 25113057 DOI: 10.1186/s12941-014-0042-4]

137 **Bae IK**, Suh B, Jeong SH, Wang KK, Kim YR, Yong D, Lee K. Molecular epidemiology of Pseudomonas aeruginosa clinical isolates from Korea producing β-lactamases with extended-spectrum activity. *Diagn Microbiol Infect Dis* 2014; **79**: 373-377 [PMID: 24792837 DOI: 10.1016/j.diagmicrobio.2014.03.007]

138 **Loli A**, Tzouvelekis LS, Tzelepi E, Carattoli A, Vatopoulos AC, Tassios PT, Miriagou V. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1. *J Antimicrob Chemother* 2006; **58**: 669-672 [PMID: 16870645 DOI: 10.1093/jac/dkl302]

139 **Johnson AP**, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. *J Med Microbiol* 2013; **62**: 499-513 [PMID: 23329317 DOI: 10.1099/jmm.0.052555-0]

140 **Perry JD**, Naqvi SH, Mirza IA, Alizai SA, Hussain A, Ghirardi S, Orenga S, Wilkinson K, Woodford N, Zhang J, Livermore DM, Abbasi SA, Raza MW. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. *J Antimicrob Chemother* 2011; **66**: 2288-2294 [PMID: 21788293 DOI: 10.1093/jac/dkr299]

141 **Day KM**, Ali S, Mirza IA, Sidjabat HE, Silvey A, Lanyon CV, Cummings SP, Abbasi SA, Raza MW, Paterson DL, Perry JD. Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. *Diagn Microbiol Infect Dis* 2013; **75**: 187-191 [PMID: 23246367 DOI: 10.1016/j.diagmicrobio.2012.11.006]

142 **Berrazeg M**, Diene S, Medjahed L, Parola P, Drissi M, Raoult D, Rolain J. New Delhi Metallo-beta-lactamase around the world: an eReview using Google Maps. *Euro Surveill* 2014; **19**: [PMID: 24871756]

143 **Slama TG**. Gram-negative antibiotic resistance: there is a price to pay. *Crit Care* 2008; **12 Suppl 4**: S4 [PMID: 18495061 DOI: 10.1186/cc6820]

144 **Wilke MH**. Multiresistant bacteria and current therapy - the economical side of the story. *Eur J Med Res* 2010; **15**: 571-576 [PMID: 21163732 DOI: 10.1186/2047-783X-15-12-571]

145 **Cosgrove SE**. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. *Clin Infect Dis* 2006; **42 Suppl 2**: S82-S89 [PMID: 16355321]

146 **Savard P**, Perl TM. Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose. *Clin Microbiol Infect* 2014; **20**: 854-861 [PMID: 24980472 DOI: 10.1111/1469-0691.12748]

147 **Ricardo Morales I.** [Treatment of extended spectrum betalactamases producing bacteria]. *Rev Chil Infectol* 2003; **20** Suppl 1: 24-27 [DOI: 10.4067/S0716-10182003020100003]

148 **Clinical and Laboratory Standars Institute.** Performance standards for antimicrobial susceptibility testing. CLSI document M100-S24. 2014. Available from: URL: http: //www.ctmperu.org.pe/anexos/bibliotecavirtual/exposiciones/guia CLSI 2014.pdf

149 **European Committee on Antimicrobial Susceptibility Testing.** 2014. Available from: URL: http: //www.eucast.org

150 **Nordmann P**, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V. Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Infect* 2012; **18**: 432-438 [PMID: 22507110 DOI: 10.1111/j.1469-0691.2012.03815.x]

151 **Vading M**, Samuelsen Ø, Haldorsen B, Sundsfjord AS, Giske CG. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. *Clin Microbiol Infect* 2011; **17**: 668-674 [PMID: 20649801 DOI: 10.1111/j.1469-0691.2010.03299.x]

152 **Pasteran F**, Lucero C, Soloaga R, Rapoport M, Corso A. Can we use imipenem and meropenem Vitek 2 MICs for detection of suspected KPC and other-carbapenemase producers among species of Enterobacteriaceae? *J Clin Microbiol* 2011; **49**: 697-701 [PMID: 21159944 DOI: 10.1128/JCM.01178-10]

153 **Day KM**, Pike R, Winstanley TG, Lanyon C, Cummings SP, Raza MW, Woodford N, Perry JD. Use of faropenem as an indicator of carbapenemase activity in the Enterobacteriaceae. *J Clin Microbiol* 2013; **51**: 1881-1886 [PMID: 23576544 DOI: 10.1128/JCM.00720-13]

154 **Harino T**, Kayama S, Kuwahara R, Kashiyama S, Shigemoto N, Onodera M, Yokozaki M, Ohge H, Sugai M. Meropenem resistance in imipenem-susceptible meropenem-resistant Klebsiella pneumoniae isolates not detected by rapid automated testing systems. *J Clin Microbiol* 2013; **51**: 2735-2738 [PMID: 23720796 DOI: 10.1128/JCM.02649-12]

155 **Bulik CC**, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP, Kuti JL. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. *J Clin Microbiol* 2010; **48**: 2402-2406 [PMID: 20484603]

156 **Woodford N**, Eastaway AT, Ford M, Leanord A, Keane C, Quayle RM, Steer JA, Zhang J, Livermore DM. Comparison of BD Phoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. *J Clin Microbiol* 2010; **48**: 2999-3002 [PMID: 20534805 DOI: 10.1128/JCM.00341-10]

157 **Pasteran F**, Veliz O, Rapoport M, Guerriero L, Corso A. Sensitive and specific modified Hodge test for KPC and metallo-beta- lactamase detection in Pseudomonas aeruginosa by use of a novel indicator strain, Klebsiella pneumoniae ATCC 700603. *J Clin Microbiol* 2011; **49**: 4301-4303 [PMID: 22012019 DOI: 10.1128/JCM.05602-11]

158 **Girlich D**, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. *J Clin Microbiol* 2012; **50**: 477-479 [PMID: 22116154 DOI: 10.1128/JCM.05247-11]

159 **Lee K**, Kim CK, Yong D, Jeong SH, Yum JH, Seo YH, Docquier JD, Chong Y. Improved performance of the modified Hodge test with MacConkey agar for screening carbapenemase-producing Gram-negative bacilli. *J Microbiol Methods* 2010; **83**: 149-152 [PMID: 20801167 DOI: 10.1016/j.mimet.2010.08.010]

160 **Pasteran F**, Mendez T, Rapoport M, Guerriero L, Corso A. Controlling false-positive results obtained with the Hodge and Masuda assays for detection of class a carbapenemase in species of enterobacteriaceae by incorporating boronic Acid. *J Clin Microbiol* 2010; **48**: 1323-1332 [PMID: 20181912 DOI: 10.1128/JCM.01771-09]

161 **Dortet L**, Poirel L, Nordmann P. Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test. *Antimicrob Agents Chemother* 2012; **56**: 6437-6440 [PMID: 23070158 DOI: 10.1128/AAC.01395-12]

162 **Nordmann P**, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2012; **18**: 1503-1507 [PMID: 22932472 DOI: 10.3201/eid1809.120355]

163 **Tijet N**, Boyd D, Patel SN, Mulvey MR, Melano RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2013; **57**: 4578-4580 [PMID: 23817380 DOI: 10.1128/AAC.00878-13]

164 **Dortet L**, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing Pseudomonas spp. *J Clin Microbiol* 2012; **50**: 3773-3776 [PMID: 22972829 DOI: 10.1128/JCM.01597-12]

165 **Dortet L**, Bréchard L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures. *Clin Microbiol Infect* 2014; **20**: 340-344 [PMID: 23889766 DOI: 10.1111/1469-0691.12318]

166 **Huang TD**, Berhin C, Bogaerts P, Glupczynski Y. Comparative evaluation of two chromogenic tests for rapid detection of carbapenemase in Enterobacteriaceae and in Pseudomonas aeruginosa isolates. *J Clin Microbiol* 2014; **52**: 3060-3063 [PMID: 24850357 DOI: 10.1128/JCM-00643-14]

167 **Pires J**, Novais A, Peixe L. Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. *J Clin Microbiol* 2013; **51**: 4281-4283 [PMID: 24108615 DOI: 10.1128/JCM.01634-13]

168 **Lee K**, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. *J Clin Microbiol* 2003; **41**: 4623-4629 [PMID: 14532193]

169 **Yong D**, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. *J Clin Microbiol* 2002; **40**: 3798-3801 [PMID: 12354884 DOI: 10.1128/JCM.40.10.3798-3801.2002]

170 **Khosravi Y**, Loke MF, Chua EG, Tay ST, Vadivelu J. Phenotypic detection of metallo-β-lactamase in imipenem-resistant Pseudomonas aeruginosa. *ScientificWorldJournal* 2012; **2012**: 654939 [PMID: 22792048 DOI: 10.1100/2012/654939]

171 **Doyle D**, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. *J Clin Microbiol* 2012; **50**: 3877-3880 [PMID: 22993175 DOI: 10.1128/JCM.02117-12]

172 **Birgy A**, Bidet P, Genel N, Doit C, Decré D, Arlet G, Bingen E. Phenotypic screening of carbapenemases and associated β-lactamases in carbapenem-resistant Enterobacteriaceae. *J Clin Microbiol* 2012; **50**: 1295-1302 [PMID: 22259214 DOI: 10.1128/JCM.06131-11]

173 **Pasteran F**, Mendez T, Guerriero L, Rapoport M, Corso A. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. *J Clin Microbiol* 2009; **47**: 1631-1639 [PMID: 19386850 DOI: 10.1128/JCM.00130-09]

174 **van Dijk K**, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, Leverstein-Van Hall MA, Cohen Stuart JW. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. *Clin Microbiol Infect* 2014; **20**: 345-349 [PMID: 23927659 DOI: 10.1111/1469-0691.12322]

175 **Huang TD**, Poirel L, Bogaerts P, Berhin C, Nordmann P, Glupczynski Y. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers. *J Antimicrob Chemother* 2014; **69**: 445-450 [PMID: 24055766 DOI: 10.1093/jac/dkt367]

176 **Nordmann P**, Girlich D, Poirel L. Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium. *J Clin Microbiol* 2012; **50**: 2761-2766 [PMID: 22357501 DOI: 10.1128/JCM.06477-11]

177 **Vrioni G**, Daniil I, Voulgari E, Ranellou K, Koumaki V, Ghirardi S, Kimouli M, Zambardi G, Tsakris A. Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. *J Clin Microbiol* 2012; **50**: 1841-1846 [PMID: 22461675 DOI: 10.1128/JCM.06848-11]

178 **Cohen Stuart J**, Voets G, Rottier W, Voskuil S, Scharringa J, Van Dijk K, Fluit AC, Leverstein-Van Hall M. Evaluation of the Oxoid Brilliance™ CRE Agar for the detection of carbapenemase-producing Enterobacteriaceae. *Eur J Clin Microbiol Infect Dis* 2013; **32**: 1445-1449 [PMID: 23728736 DOI: 10.1007/s100096-013-1896-7]

179 Biomerieux. Available from: URL: http: //www.biomerieux-diagnostics.com/chromid-carba-smart

180 **Poirel L**, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis* 2011; **70**: 119-123 [PMID: 21398074 DOI: 10.1016/j.diagmicrobio.2010.12.002]

181 **Kaase M**, Szabados F, Wassill L, Gatermann SG. Detection of carbapenemases in Enterobacteriaceae by a commercial multiplex PCR. *J Clin Microbiol* 2012; **50**: 3115-3118 [PMID: 22785190 DOI: 10.1128/JCM.00991-12]

182 **van der Zee A**, Roorda L, Bosman G, Fluit AC, Hermans M, Smits PH, van der Zanden AG, Te Witt R, Bruijnesteijn van Coppenraet LE, Cohen Stuart J, Ossewaarde JM. Multi-centre evaluation of real-time multiplex PCR for detection of carbapenemase genes OXA-48, VIM, IMP, NDM and KPC. *BMC Infect Dis* 2014; **14**: 27 [PMID: 24422880 DOI: 10.1186/1471-2334-14-27]

183 **Monteiro J**, Widen RH, Pignatari AC, Kubasek C, Silbert S. Rapid detection of carbapenemase genes by multiplex real-time PCR. *J Antimicrob Chemother* 2012; **67**: 906-909 [PMID: 22232516 DOI: 10.1093/jac/dkr563]

184 **Tenover FC**, Canton R, Kop J, Chan R, Ryan J, Weir F, Ruiz-Garbajosa P, LaBombardi V, Persing DH. Detection of colonization by carbapenemase-producing Gram-negative Bacilli in patients by use of the Xpert MDRO assay. *J Clin Microbiol* 2013; **51**: 3780-3787 [PMID: 24006011 DOI: 10.1128/JCM.01092-13]

185 **Naas T**, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum β-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. *J Clin Microbiol* 2011; **49**: 1608-1613 [PMID: 21325547 DOI: 10.1128/JCM.02607-10]

186 **Bernabeu S**, Poirel L, Nordmann P. Spectrophotometry-based detection of carbapenemase producers among Enterobacteriaceae. *Diagn Microbiol Infect Dis* 2012; **74**: 88-90 [PMID: 22727768 DOI: 10.1016/j.diagmicrobio.2012.05.02]

187 **Sparbier K**, Schubert S, Weller U, Boogen C, Kostrzewa M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against β-lactam antibiotics. *J Clin Microbiol* 2012; **50**: 927-937 [PMID: 22205812 DOI: 10.1128/JCM.05737-11]

188 **Hrabák J**, Studentová V, Walková R, Zemlicková H, Jakubu V, Chudácková E, Gniadkowski M, Pfeifer Y, Perry JD, Wilkinson K, Bergerová T. Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2012; **50**: 2441-2443 [PMID: 22553235 DOI: 10.1128/JCM.01002-12]

189 **Pan C**, Xu S, Zhou H, Fu Y, Ye M, Zou H. Recent developments in methods and technology for analysis of biological samples by MALDI-TOF-MS. *Anal Bioanal Chem* 2007; **387**: 193-204 [PMID: 17086385]

190 **Hrabák J**, Walková R, Studentová V, Chudácková E, Bergerová T. Carbapenemase activity detection by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2011; **49**: 3222-3227 [PMID: 21775535]

191 **Carvalhaes CG**, Cayô R, Assis DM, Martins ER, Juliano L, Juliano MA, Gales AC. Detection of SPM-1-producing Pseudomonas aeruginosa and class D β-lactamase-producing Acinetobacter baumannii isolates by use of liquid chromatography-mass spectrometry and matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* 2013; **51**: 287-290 [PMID: 23100344 DOI: 10.1128/JCM.02365-12]

192 **Hooff GP**, van Kampen JJ, Meesters RJ, van Belkum A, Goessens WH, Luider TM. Characterization of β-lactamase enzyme activity in bacterial lysates using MALDI-mass spectrometry. *J Proteome Res* 2012; **11**: 79-84 [PMID: 22013912 DOI: 10.1021/pr200858r]

193 **Carvalhaes CG**, Cayô R, Visconde MF, Barone T, Frigatto EA, Okamoto D, Assis DM, Juliano L, Machado AM, Gales AC. Detection of carbapenemase activity directly from blood culture vials using MALDI-TOF MS: a quick answer for the right decision. *J Antimicrob Chemother* 2014; **69**: 2132-2136 [PMID: 24722840]

194 **Gasink LB**, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. *Infect Control Hosp Epidemiol* 2009; **30**: 1180-1185 [PMID: 19860564 DOI: 10.1086/648451]

195 **Papadimitriou-Olivgeris M**, Marangos M, Fligou F, Christofidou M, Bartzavali C, Anastassiou ED, Filos KS. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. *J Antimicrob Chemother* 2012; **67**: 2976-2981 [PMID: 22927316 DOI: 10.1093/jac/dks316]

196 **Rogers BA**, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. *Clin Infect Dis* 2011; **53**: 49-56 [PMID: 21653302 DOI: 10.1093/cid/cir273]

197 **Ohmagari N**, Kurai H, Yamagishi Y, Mikamo H. Are strict isolation policies based on susceptibility testing actually effective in the prevention of the nosocomial spread of multi-drug-resistant gram-negative rods? *Am J Infect Control* 2014; **42**: 739-743 [PMID: 24969125 DOI: 10.1016/j.ajic.2014.04.003]

198 **Gómez-Zorrilla S**, Camoez M, Tubau F, Periche E, Cañizares R, Dominguez MA, Ariza J, Peña C. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. *Antimicrob Agents Chemother* 2014; **58**: 5863-5870 [PMID: 25049255 DOI: 10.1128/AAC.03419-14]

199 **Hawkey PM**. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. *Clin Microbiol Infect* 2008; **14 Suppl 1**: 159-165 [PMID: 18154540 DOI: 10.1128/AAC.00666-12]

200 **Landman D**, Singh M, El-Imad B, Miller E, Win T, Quale J. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. *Int J Antimicrob Agents* 2014; **43**: 527-532 [PMID: 24796217 DOI: 10.1016/j.ijantimicag.2014.02.017]

201 **Galani I**, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H, Petrikkos G. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. *J Chemother* 2012; **24**: 191-194 [PMID: 23040681 DOI: 10.1179/1973947812Y.0000000015]

202 **Almaghrabi R**, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. *Antimicrob Agents Chemother* 2014; **58**: 4443-4451 [PMID: 24867988]

203 **Sutcliffe JA**. Antibiotics in development targeting protein synthesis. *Ann N Y Acad Sci* 2011; **1241**: 122-152 [PMID: 22191530 DOI: 10.1111/j.1749-6632.2011.06323.x]

204 **King DT**, Strynadka NC. Targeting metallo-β-lactamase enzymes in antibiotic resistance. *Future Med Chem* 2013; **5**: 1243-1263 [PMID: 23859206 DOI: 10.4155/fmc.13.55]

205 **Livermore DM**, Woodford N. Carbapenemases: a problem in waiting? *Curr Opin Microbiol* 2000; **3**: 489-495 [PMID: 11050448]

206 **Walsh TR**. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria. *Clin Microbiol Infect* 2005; **11** Suppl 6: 2-9 [PMID: 16209700]

207 **Nordmann P**, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! *Trends Mol Med* 2012; **18**: 263-272 [PMID: 22480775 DOI: 10.1016/j.molmed.2012.03.003]

**P-Reviewer:** Al-Tawfiq JA, Gallego L **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Carbapenemase classification**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Bush-Jacoby (2010)** | **Bush-Jacoby-Medeiros  (1995)** | **Molecular  class** | **Distinctive  substrate** | **Inhibited by** | | **Characteristics** | **Representative enzyme** |
| **CA or TZB** | **EDTA** |
| 2f | 2f | A | Carbapenems | variable | no | Increased hydrolysis of carbapenems,  oxyamino-beta-lactams, cephamycins | KPC-2, IMI-1, SME-1 |
| 2df |  | D | Carbapenems | variable | no | Hydrolizes oxacillin and carbapenems | OXA-23, OXA-48 |
| 1e |  | C | Cephalosporins | no | no | Increased hydrolysis of ceftazidime and often other oxyimino-ß-lactams | CMY-10 |
| 3a | 3 | B1 | Carbapenems | no | yes | Broad.spectrum hydrolysis including  carbapenems but not monobactams | IMP-1, VIM-1, CcrA, IND-1 |
| 3a | 3 | B3 | Cephalosporins | no | yes | Broad.spectrum hydrolysis including  carbapenems but not monobactams | L1, CAU-1, GOB-1, FEZ-1 |
| 3b | 3 | B2 | Carbapenems | no | yes | Preferential hydrolysis of carbapenems | CphA, SFh-1 |

CA: Clavulanic acid; TZB: Tazobactam.

**Table 2 OXA-type clusters**

|  |  |  |  |
| --- | --- | --- | --- |
| **Cluster** | **Subfamily** | **Other members** | **Microorganisms associated** |
| 1 | OXA-23 | OXA-27, OXA-29 | *Acinetobacter* spp. |
| 2 | OXA-24/40 | OXA-25, OXA-26, OXA-72 | *Acinetobacter* spp. and *P. aeruginosa* |
| 3 | OXA-51 | OXA-64-71, OXA-75-78,OXA-83, OXA-84, OXA-86-89, OXA-91, OXA-92, OXA-94, OXA-95 | *Acinetobacter* spp. |
| 4 | OXA-58 |  | *Acinetobacter* spp. |
| 5 | OXA-55 | OXA-SHE | *Shewanella* spp. |
| 6 | OXA-48 | OXA-54, OXA-181, OXA-163, OXA-204, OXA-232, OXA-247, OXA-SAR2 | *Enterobacteriaceae* |
| 7 | OXA-50 | OXA-50a-d, POXB | *P. aeruginosa.* |
| 8 | OXA-60 | OXA-60a-d | *Ralstonia* *pickettii* |
| 9 | OXA-62 |  | *Pandoraea* *pnomenusa* |

**Table 3 Breakpoint and screening cut-off for carbapenemase-producing *Enterobacteriaceae***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **MIC (mg/L)** | | | | **Disk-diffusion zone diameter (mm)  using 10 *µg* disks** | | | |
|  | S breakpoint | | Screening cut-off | | S breakpoint | | Screening cut-off | |
|  | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI |
| **Meropenem** | ≤ 2 | ≤ 1 | > 0.12 | 2-4 | ≥ 22 | ≥ 23 | < 25 | 16-21 |
| **Imipenem** | ≤ 2 | ≤ 1 | > 1 | 2-4 | ≥ 22 | ≥ 23 | < 23 | - |
| **Ertapenem** | ≤ 0.5 | ≤ 0.5 | > 0.12 | 2-4 | ≥ 25 | ≥ 22 | < 25 | 19-21 |

S: Susceptibility.